View:
Download DOC
Download PDF
Download XLS
Download XBRL
iff-20240930
000005125312/312024Q3falsehttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiff:Positioniff:positioniff:segmentiso4217:EURiff:swap00000512532024-01-012024-09-300000051253dei:OtherAddressMember2024-01-012024-09-300000051253us-gaap:CommonStockMember2024-01-012024-09-300000051253iff:A1.800SeniorNotesDue2026Member2024-01-012024-09-3000000512532024-10-2900000512532024-07-012024-09-3000000512532023-07-012023-09-3000000512532023-01-012023-09-3000000512532024-09-3000000512532023-12-310000051253us-gaap:CommonStockMember2023-06-300000051253us-gaap:AdditionalPaidInCapitalMember2023-06-300000051253us-gaap:RetainedEarningsMember2023-06-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000051253us-gaap:TreasuryStockCommonMember2023-06-300000051253us-gaap:NoncontrollingInterestMember2023-06-3000000512532023-06-300000051253us-gaap:RetainedEarningsMember2023-07-012023-09-300000051253us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000051253us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000051253us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000051253us-gaap:CommonStockMember2023-09-300000051253us-gaap:AdditionalPaidInCapitalMember2023-09-300000051253us-gaap:RetainedEarningsMember2023-09-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000051253us-gaap:TreasuryStockCommonMember2023-09-300000051253us-gaap:NoncontrollingInterestMember2023-09-3000000512532023-09-300000051253us-gaap:CommonStockMember2024-06-300000051253us-gaap:AdditionalPaidInCapitalMember2024-06-300000051253us-gaap:RetainedEarningsMember2024-06-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000051253us-gaap:TreasuryStockCommonMember2024-06-300000051253us-gaap:NoncontrollingInterestMember2024-06-3000000512532024-06-300000051253us-gaap:RetainedEarningsMember2024-07-012024-09-300000051253us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000051253us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000051253us-gaap:TreasuryStockCommonMember2024-07-012024-09-300000051253us-gaap:CommonStockMember2024-09-300000051253us-gaap:AdditionalPaidInCapitalMember2024-09-300000051253us-gaap:RetainedEarningsMember2024-09-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000051253us-gaap:TreasuryStockCommonMember2024-09-300000051253us-gaap:NoncontrollingInterestMember2024-09-300000051253us-gaap:CommonStockMember2022-12-310000051253us-gaap:AdditionalPaidInCapitalMember2022-12-310000051253us-gaap:RetainedEarningsMember2022-12-310000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000051253us-gaap:TreasuryStockCommonMember2022-12-310000051253us-gaap:NoncontrollingInterestMember2022-12-3100000512532022-12-310000051253us-gaap:RetainedEarningsMember2023-01-012023-09-300000051253us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000051253us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000051253us-gaap:TreasuryStockCommonMember2023-01-012023-09-300000051253us-gaap:CommonStockMember2023-12-310000051253us-gaap:AdditionalPaidInCapitalMember2023-12-310000051253us-gaap:RetainedEarningsMember2023-12-310000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000051253us-gaap:TreasuryStockCommonMember2023-12-310000051253us-gaap:NoncontrollingInterestMember2023-12-310000051253us-gaap:RetainedEarningsMember2024-01-012024-09-300000051253us-gaap:NoncontrollingInterestMember2024-01-012024-09-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000051253us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300000051253us-gaap:TreasuryStockCommonMember2024-01-012024-09-300000051253srt:ScenarioPreviouslyReportedMember2023-07-012023-09-300000051253srt:ScenarioPreviouslyReportedMember2023-01-012023-09-300000051253iff:TradeAccountsReceivableWithTheCompanysOwnFactoringAgreementsMember2024-09-300000051253iff:TradeAccountsReceivableWithTheCompanysOwnFactoringAgreementsMember2024-01-012024-09-300000051253iff:TradeAccountsReceivableWithTheCompanysOwnFactoringAgreementsMember2023-01-012023-09-300000051253iff:TradeAccountsReceivableWithTheCompanysOwnFactoringAgreementsMember2023-12-310000051253iff:EmployeeStockOptionAndRestrictedStockMember2024-07-012024-09-300000051253iff:EmployeeStockOptionAndRestrictedStockMember2023-07-012023-09-300000051253iff:EmployeeStockOptionAndRestrictedStockMember2024-01-012024-09-300000051253iff:EmployeeStockOptionAndRestrictedStockMember2023-01-012023-09-300000051253iff:ShareEquivalentsMember2024-07-012024-09-300000051253iff:ShareEquivalentsMember2023-07-012023-09-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2024-04-022024-04-020000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2024-04-020000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2024-01-012024-09-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2024-07-012024-09-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2023-07-012024-06-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2023-07-012023-12-310000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:FlavorsAndEssencesUKMember2024-09-012024-09-010000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:FlavorsAndEssencesUKMember2024-09-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:FlavorsAndEssencesUKMember2024-07-012024-09-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:FlavorSpecialtyIngredientsMember2023-08-012023-08-010000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:FlavorSpecialtyIngredientsMember2023-08-010000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:FlavorSpecialtyIngredientsMember2023-01-012023-09-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:FlavorSpecialtyIngredientsMember2023-07-012023-09-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:FlavorSpecialtyIngredientsMember2024-01-012024-09-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:SavorySolutionsMember2023-05-312023-05-310000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:SavorySolutionsMember2023-05-310000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:SavorySolutionsMember2023-01-012023-09-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:SavorySolutionsMember2023-07-012023-09-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:SavorySolutionsMember2023-10-012023-12-310000051253country:RUiff:SavorySolutionsMemberus-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember2023-01-012023-09-300000051253iff:PharmaSolutionsMember2024-01-012024-09-300000051253us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberiff:PharmaSolutionsMember2024-09-300000051253us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberiff:PharmaSolutionsMember2024-01-012024-09-300000051253us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberiff:PharmaSolutionsMember2024-07-012024-09-300000051253us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberiff:SavorySolutionsBusinessTurkeyMember2024-07-012024-09-300000051253us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberiff:SavorySolutionsBusinessTurkeyMember2024-01-012024-09-300000051253us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2024-09-300000051253us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2023-12-310000051253us-gaap:EmployeeSeveranceMemberiff:NutritionAndBiosciencesRestructuringLiabilityMember2024-07-012024-09-300000051253us-gaap:EmployeeSeveranceMemberiff:NutritionAndBiosciencesRestructuringLiabilityMember2024-01-012024-09-300000051253iff:NutritionAndBiosciencesRestructuringLiabilityMember2024-01-012024-09-300000051253iff:NutritionAndBiosciencesRestructuringLiabilityMember2023-07-012023-09-300000051253iff:NutritionAndBiosciencesRestructuringLiabilityMember2023-01-012023-09-300000051253iff:NutritionAndBiosciencesRestructuringLiabilityMember2024-09-300000051253iff:A2023RestructuringProgramMember2024-07-012024-09-300000051253iff:A2023RestructuringProgramMember2024-01-012024-09-300000051253iff:A2023RestructuringProgramMember2023-07-012023-09-300000051253iff:A2023RestructuringProgramMember2023-01-012023-09-300000051253iff:A2023RestructuringProgramMember2024-09-300000051253us-gaap:OtherRestructuringMemberiff:NutritionAndBiosciencesRestructuringLiabilityMember2023-12-310000051253us-gaap:OtherRestructuringMemberiff:NutritionAndBiosciencesRestructuringLiabilityMember2024-01-012024-09-300000051253us-gaap:OtherRestructuringMemberiff:NutritionAndBiosciencesRestructuringLiabilityMember2024-09-300000051253us-gaap:EmployeeSeveranceMemberiff:A2023RestructuringProgramMember2023-12-310000051253us-gaap:EmployeeSeveranceMemberiff:A2023RestructuringProgramMember2024-01-012024-09-300000051253us-gaap:EmployeeSeveranceMemberiff:A2023RestructuringProgramMember2024-09-300000051253iff:NourishMember2024-07-012024-09-300000051253iff:NourishMember2023-07-012023-09-300000051253iff:NourishMember2024-01-012024-09-300000051253iff:NourishMember2023-01-012023-09-300000051253iff:HealthBiosciencesMember2024-07-012024-09-300000051253iff:HealthBiosciencesMember2023-07-012023-09-300000051253iff:HealthBiosciencesMember2024-01-012024-09-300000051253iff:HealthBiosciencesMember2023-01-012023-09-300000051253iff:ScentMember2024-07-012024-09-300000051253iff:ScentMember2023-07-012023-09-300000051253iff:ScentMember2024-01-012024-09-300000051253iff:ScentMember2023-01-012023-09-300000051253iff:PharmaSolutionsMember2024-07-012024-09-300000051253iff:PharmaSolutionsMember2023-07-012023-09-300000051253iff:PharmaSolutionsMember2023-01-012023-09-300000051253iff:EquityBasedAwardsMember2024-07-012024-09-300000051253iff:EquityBasedAwardsMember2023-07-012023-09-300000051253iff:EquityBasedAwardsMember2024-01-012024-09-300000051253iff:EquityBasedAwardsMember2023-01-012023-09-300000051253iff:LiabilityBasedAwardsMember2024-07-012024-09-300000051253iff:LiabilityBasedAwardsMember2023-07-012023-09-300000051253iff:LiabilityBasedAwardsMember2024-01-012024-09-300000051253iff:LiabilityBasedAwardsMember2023-01-012023-09-300000051253us-gaap:OperatingSegmentsMemberiff:NourishMember2024-07-012024-09-300000051253us-gaap:OperatingSegmentsMemberiff:NourishMember2023-07-012023-09-300000051253us-gaap:OperatingSegmentsMemberiff:NourishMember2024-01-012024-09-300000051253us-gaap:OperatingSegmentsMemberiff:NourishMember2023-01-012023-09-300000051253us-gaap:OperatingSegmentsMemberiff:HealthBiosciencesMember2024-07-012024-09-300000051253us-gaap:OperatingSegmentsMemberiff:HealthBiosciencesMember2023-07-012023-09-300000051253us-gaap:OperatingSegmentsMemberiff:HealthBiosciencesMember2024-01-012024-09-300000051253us-gaap:OperatingSegmentsMemberiff:HealthBiosciencesMember2023-01-012023-09-300000051253us-gaap:OperatingSegmentsMemberiff:ScentMember2024-07-012024-09-300000051253us-gaap:OperatingSegmentsMemberiff:ScentMember2023-07-012023-09-300000051253us-gaap:OperatingSegmentsMemberiff:ScentMember2024-01-012024-09-300000051253us-gaap:OperatingSegmentsMemberiff:ScentMember2023-01-012023-09-300000051253us-gaap:OperatingSegmentsMemberiff:PharmaSolutionsMember2024-07-012024-09-300000051253us-gaap:OperatingSegmentsMemberiff:PharmaSolutionsMember2023-07-012023-09-300000051253us-gaap:OperatingSegmentsMemberiff:PharmaSolutionsMember2024-01-012024-09-300000051253us-gaap:OperatingSegmentsMemberiff:PharmaSolutionsMember2023-01-012023-09-300000051253us-gaap:EMEAMember2024-07-012024-09-300000051253us-gaap:EMEAMember2023-07-012023-09-300000051253us-gaap:EMEAMember2024-01-012024-09-300000051253us-gaap:EMEAMember2023-01-012023-09-300000051253srt:AsiaMember2024-07-012024-09-300000051253srt:AsiaMember2023-07-012023-09-300000051253srt:AsiaMember2024-01-012024-09-300000051253srt:AsiaMember2023-01-012023-09-300000051253srt:NorthAmericaMember2024-07-012024-09-300000051253srt:NorthAmericaMember2023-07-012023-09-300000051253srt:NorthAmericaMember2024-01-012024-09-300000051253srt:NorthAmericaMember2023-01-012023-09-300000051253srt:LatinAmericaMember2024-07-012024-09-300000051253srt:LatinAmericaMember2023-07-012023-09-300000051253srt:LatinAmericaMember2024-01-012024-09-300000051253srt:LatinAmericaMember2023-01-012023-09-300000051253country:USus-gaap:GeographicConcentrationRiskMember2024-07-012024-09-300000051253country:USus-gaap:GeographicConcentrationRiskMember2023-07-012023-09-300000051253country:USus-gaap:GeographicConcentrationRiskMember2024-01-012024-09-300000051253country:USus-gaap:GeographicConcentrationRiskMember2023-01-012023-09-300000051253iff:AllForeignCountriesMemberus-gaap:GeographicConcentrationRiskMember2024-07-012024-09-300000051253iff:AllForeignCountriesMemberus-gaap:GeographicConcentrationRiskMember2023-07-012023-09-300000051253iff:AllForeignCountriesMemberus-gaap:GeographicConcentrationRiskMember2024-01-012024-09-300000051253iff:AllForeignCountriesMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-09-300000051253iff:AllForeignCountriesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesMember2023-07-012023-09-300000051253iff:AllForeignCountriesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesMember2024-07-012024-09-300000051253country:USus-gaap:PensionPlansDefinedBenefitMember2024-07-012024-09-300000051253country:USus-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300000051253country:USus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-09-300000051253country:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300000051253us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-07-012024-09-300000051253us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300000051253us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-09-300000051253us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300000051253country:USus-gaap:PensionPlansDefinedBenefitMember2024-09-300000051253us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-09-300000051253country:USus-gaap:QualifiedPlanMember2024-01-012024-09-300000051253country:USus-gaap:NonqualifiedPlanMember2024-01-012024-09-300000051253us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-07-012024-09-300000051253us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-07-012023-09-300000051253us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-09-300000051253us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-09-300000051253us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-09-300000051253us-gaap:OtherLiabilitiesMember2024-09-300000051253us-gaap:ForeignCountryMember2024-09-300000051253us-gaap:DomesticCountryMember2024-09-300000051253us-gaap:LandMember2024-09-300000051253us-gaap:LandMember2023-12-310000051253us-gaap:BuildingAndBuildingImprovementsMember2024-09-300000051253us-gaap:BuildingAndBuildingImprovementsMember2023-12-310000051253us-gaap:MachineryAndEquipmentMember2024-09-300000051253us-gaap:MachineryAndEquipmentMember2023-12-310000051253us-gaap:TechnologyEquipmentMember2024-09-300000051253us-gaap:TechnologyEquipmentMember2023-12-310000051253us-gaap:ConstructionInProgressMember2024-09-300000051253us-gaap:ConstructionInProgressMember2023-12-310000051253iff:NourishMember2023-12-310000051253iff:HealthBiosciencesMember2023-12-310000051253iff:ScentMember2023-12-310000051253iff:PharmaSolutionsMember2023-12-310000051253iff:NourishMember2024-09-300000051253iff:HealthBiosciencesMember2024-09-300000051253iff:ScentMember2024-09-300000051253iff:PharmaSolutionsMember2024-09-300000051253us-gaap:CustomerRelationshipsMember2024-09-300000051253us-gaap:CustomerRelationshipsMember2023-12-310000051253us-gaap:TechnologyBasedIntangibleAssetsMember2024-09-300000051253us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000051253us-gaap:TrademarksAndTradeNamesMember2024-09-300000051253us-gaap:TrademarksAndTradeNamesMember2023-12-310000051253us-gaap:OtherIntangibleAssetsMember2024-09-300000051253us-gaap:OtherIntangibleAssetsMember2023-12-310000051253iff:HealthWrightProductsIncHealthWrightMember2024-07-012024-09-300000051253iff:HealthWrightProductsIncHealthWrightMember2024-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:LoansPayableMember2024-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandTwentyFiveMemberus-gaap:LoansPayableMember2024-09-300000051253iff:SeniorNotesDueTwoThousandTwentyFiveMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:LoansPayableMember2024-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandTwentySevenMemberus-gaap:LoansPayableMember2024-09-300000051253iff:SeniorNotesDueTwoThousandTwentySevenMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandTwentyEightMemberus-gaap:LoansPayableMember2024-09-300000051253iff:SeniorNotesDueTwoThousandTwentyEightMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandThirtyMemberus-gaap:LoansPayableMember2024-09-300000051253iff:SeniorNotesDueTwoThousandThirtyMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFortyMemberus-gaap:LoansPayableMember2024-09-300000051253iff:SeniorNotesDueTwoThousandFortyMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFortySevenMemberus-gaap:LoansPayableMember2024-09-300000051253iff:SeniorNotesDueTwoThousandFortySevenMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFortyEightMemberus-gaap:LoansPayableMember2024-09-300000051253iff:SeniorNotesDueTwoThousandFortyEightMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFiftyMemberus-gaap:LoansPayableMember2024-09-300000051253iff:SeniorNotesDueTwoThousandFiftyMemberus-gaap:LoansPayableMember2023-12-310000051253iff:A2024TermLoanMemberus-gaap:LoansPayableMember2024-09-300000051253iff:A2024TermLoanMemberus-gaap:LoansPayableMember2023-12-310000051253iff:A2026TermLoanMemberus-gaap:LoansPayableMember2024-09-300000051253iff:A2026TermLoanMemberus-gaap:LoansPayableMember2023-12-310000051253us-gaap:RevolvingCreditFacilityMemberus-gaap:LoansPayableMember2024-09-300000051253us-gaap:RevolvingCreditFacilityMemberus-gaap:LoansPayableMember2023-12-310000051253iff:BankBorrowingsAndOverdraftsMember2024-09-300000051253iff:BankBorrowingsAndOverdraftsMember2023-12-310000051253iff:CitibankN.AMemberus-gaap:RevolvingCreditFacilityMemberiff:EurocurrencyRateMembersrt:MinimumMember2021-07-282021-07-280000051253iff:CitibankN.AMemberus-gaap:RevolvingCreditFacilityMemberiff:EurocurrencyRateMembersrt:MaximumMember2021-07-282021-07-280000051253iff:CitibankN.AMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMember2021-07-282021-07-280000051253iff:CitibankN.AMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MaximumMember2021-07-282021-07-280000051253iff:CitibankN.AMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-09-300000051253iff:CitibankN.AMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-09-300000051253iff:A2024TermLoanMemberus-gaap:LoansPayableMember2024-01-012024-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:LoansPayableMember2024-01-012024-09-300000051253iff:A2026TermLoanMemberus-gaap:LoansPayableMember2024-01-012024-09-300000051253iff:SeniorNotesDueTwoThousandTwentyThreeMemberus-gaap:LoansPayableMember2023-01-012023-09-300000051253us-gaap:RevolvingCreditFacilityMemberus-gaap:LoansPayableMember2023-01-012023-09-300000051253iff:A2024TermLoanMemberus-gaap:LoansPayableMember2023-01-012023-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyFiveMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyFiveMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyFiveMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyFiveMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentySixMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentySixMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentySixMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentySixMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentySevenMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentySevenMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentySevenMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentySevenMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyEightMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyEightMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyEightMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyEightMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandThirtyMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandThirtyMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandThirtyMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandThirtyMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortySevenMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortySevenMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortySevenMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortySevenMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyEightMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyEightMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyEightMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyEightMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFiftyMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFiftyMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFiftyMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFiftyMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:A2024TermLoanMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:A2024TermLoanMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:A2024TermLoanMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:A2024TermLoanMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:A2026TermLoanMember2024-09-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:A2026TermLoanMember2024-09-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:A2026TermLoanMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:A2026TermLoanMember2023-12-310000051253iff:EuroNotesMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000051253iff:A2022CrossCurrencySwapsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000051253iff:A2022CrossCurrencySwapsMemberus-gaap:NetInvestmentHedgingMember2024-09-300000051253us-gaap:ForwardContractsMember2024-09-300000051253us-gaap:ForwardContractsMember2023-12-310000051253us-gaap:CommodityContractMember2024-09-300000051253us-gaap:CommodityContractMember2023-12-310000051253us-gaap:CurrencySwapMember2024-09-300000051253us-gaap:CurrencySwapMember2023-12-310000051253us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000051253us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-09-300000051253us-gaap:ForeignExchangeContractMember2024-09-300000051253us-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000051253us-gaap:NondesignatedMember2024-09-300000051253us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000051253us-gaap:CurrencySwapMemberus-gaap:NondesignatedMember2024-09-300000051253us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000051253us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-12-310000051253us-gaap:ForeignExchangeContractMember2023-12-310000051253us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000051253us-gaap:NondesignatedMember2023-12-310000051253us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000051253us-gaap:CurrencySwapMemberus-gaap:NondesignatedMember2023-12-310000051253us-gaap:ForeignExchangeContractMember2024-07-012024-09-300000051253us-gaap:ForeignExchangeContractMember2023-07-012023-09-300000051253us-gaap:ForeignExchangeContractMember2024-01-012024-09-300000051253us-gaap:ForeignExchangeContractMember2023-01-012023-09-300000051253us-gaap:CommodityContractMember2024-01-012024-09-300000051253us-gaap:CommodityContractMember2023-01-012023-09-300000051253iff:CrossCurrencySwapsMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300000051253iff:CrossCurrencySwapsMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300000051253iff:CrossCurrencySwapsMemberus-gaap:NetInvestmentHedgingMember2024-07-012024-09-300000051253iff:CrossCurrencySwapsMemberus-gaap:NetInvestmentHedgingMember2023-07-012023-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:NetInvestmentHedgingMember2024-07-012024-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:NetInvestmentHedgingMember2023-07-012023-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:NetInvestmentHedgingMember2024-07-012024-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:NetInvestmentHedgingMember2023-07-012023-09-300000051253iff:ForeignCurrencyContractsMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300000051253iff:ForeignCurrencyContractsMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300000051253iff:CrossCurrencySwapsMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300000051253iff:CrossCurrencySwapsMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300000051253iff:CrossCurrencySwapsMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-09-300000051253iff:CrossCurrencySwapsMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-09-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-09-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-07-012024-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-07-012024-09-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-12-310000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000051253us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-01-012024-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-07-012023-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012023-09-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-12-310000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000051253us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-01-012023-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2024-07-012024-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-07-012023-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-07-012024-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-07-012023-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2024-01-012024-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-01-012023-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-01-012024-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-01-012023-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000051253iff:BankGuaranteesCommercialGuaranteesStandbyLettersOfCreditAndSuretyBondsMember2024-09-300000051253iff:PledgedAssetsMember2024-09-300000051253iff:CitibankN.AMemberus-gaap:RevolvingCreditFacilityMember2024-09-300000051253srt:ChiefExecutiveOfficerMember2019-10-292019-10-290000051253srt:ChiefExecutiveOfficerMember2020-03-112020-03-110000051253us-gaap:UnfavorableRegulatoryActionMember2024-01-012024-03-310000051253iff:WastewaterDisposalMemberiff:SolaeLLCMemphisMember2024-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                         
Commission file number 1-4858
 INTERNATIONAL FLAVORS & FRAGRANCES INC.
(Exact name of registrant as specified in its charter)
New York13-1432060
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
521 West 57th Street, New York, NY 10019-2960
200 Powder Mill Road, Wilmington, DE 19803-2907
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (212) 765-5500
 Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange
on which registered
Common Stock, par value 12 1/2¢ per shareIFFNew York Stock Exchange
1.800% Senior Notes due 2026IFF 26New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☑    No   ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☑   No   ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☑Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes   ☐ No  ☑ 
Number of shares of common stock outstanding as of October 29, 2024: 255,682,329


INTERNATIONAL FLAVORS & FRAGRANCES INC.
TABLE OF CONTENTS
  PAGE
PART I - Financial Information
ITEM 1.
ITEM 2.
ITEM 3.
ITEM 4.
PART II - Other Information
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 5.
ITEM 6.

Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
INTERNATIONAL FLAVORS & FRAGRANCES INC.
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)
Three Months EndedNine Months Ended
 September 30,September 30,
(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)2024202320242023
Net sales$2,925 $2,820 $8,713 $8,776 
Cost of Sales1,873 1,896 5,569 5,955 
Gross profit1,052 924 3,144 2,821 
Research and development expenses162 157 501 479 
Selling and administrative expenses495 444 1,478 1,343 
Amortization of acquisition-related intangibles146 170 467 513 
Impairment of goodwill— — 64 — 
Restructuring and other charges1 2 6 61 
(Gains) losses on sale of assets(1)1 (11)(1)
Operating profit249 150 639 426 
Interest expense74 90 236 291 
(Gains) losses on business disposals20 10 (348)29 
Loss on assets classified as held for sale32 — 314 — 
Other expense (income), net28 (9)44 (17)
Income before income taxes95 59 393 123 
Provision for income taxes35 32 100 77 
Net income60 27 293 46 
Net income attributable to non-controlling interests1 2 4 3 
Net income attributable to IFF shareholders$59 $25 $289 $43 
Net income per share - basic and diluted$0.23 $0.10 $1.13 $0.16 
Average number of shares outstanding - basic256 255 255 255 
Average number of shares outstanding - diluted257 256 256 255 
Statements of Comprehensive Income (Loss)
Net income$60 $27 $293 $46 
Other comprehensive income (loss), after tax:
Foreign currency translation adjustments555 (476)134 (132)
Gains (losses) on derivatives qualifying as hedges1 — (5)— 
Pension and postretirement liability adjustment(1)(3)7 (6)
Other comprehensive income (loss)555 (479)136 (138)
Comprehensive income (loss)615 (452)429 (92)
Comprehensive income attributable to non-controlling interests1 2 4 3 
Comprehensive income (loss) attributable to IFF shareholders$614 $(454)$425 $(95)

See Notes to Consolidated Financial Statements
1
Table of Contents
INTERNATIONAL FLAVORS & FRAGRANCES INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)September 30, 2024December 31, 2023
ASSETS
Current Assets:
Cash, cash equivalents, and restricted cash$567 $709 
Trade receivables (net of allowances)1,772 1,726 
Inventories2,200 2,477 
Assets held for sale3,114 506 
Prepaid expenses and other current assets770 875 
Total Current Assets8,423 6,293 
Property, plant and equipment, net3,772 4,240 
Goodwill9,349 10,635 
Other intangible assets, net6,770 8,357 
Operating lease right-of-use assets646 689 
Other assets968 764 
Total Assets$29,928 $30,978 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Short-term debt and current portion of long-term debt$468 $885 
Accounts payable1,211 1,378 
Accrued payroll and bonus382 265 
Dividends payable102 207 
Liabilities held for sale304 46 
Other current liabilities751 977 
Total Current Liabilities3,218 3,758 
Other Liabilities:
Long-term debt8,631 9,186 
Retirement liabilities182 253 
Deferred income taxes1,869 1,937 
Operating lease liabilities605 642 
Other liabilities613 560 
Total Other Liabilities11,900 12,578 
Commitments and Contingencies (Note 17)
Shareholders’ Equity:
Common stock $0.125 par value; 500.0 shares authorized; 275.7 shares issued as of September 30, 2024 and December 31, 2023; and 255.7 and 255.3 shares outstanding as of September 30, 2024 and December 31, 2023, respectively
35 35 
Capital in excess of par value19,902 19,874 
Accumulated deficit(2,457)(2,439)
Accumulated other comprehensive loss(1,760)(1,896)
Treasury stock, at cost (20.0 and 20.4 shares as of September 30, 2024 and December 31, 2023, respectively)
(945)(963)
Total Shareholders’ Equity14,775 14,611 
Non-controlling interests35 31 
Total Shareholders’ Equity including Non-controlling interests14,810 14,642 
Total Liabilities and Shareholders’ Equity$29,928 $30,978 
See Notes to Consolidated Financial Statements
2
Table of Contents
INTERNATIONAL FLAVORS & FRAGRANCES INC.
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(Unaudited)
(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)Common
stock		Capital in
excess of
par value		Retained
earnings		Accumulated  other
comprehensive
(loss) income		Treasury stockNon-controlling
interest		Total
SharesCostSharesCost
Balance at July 1, 2023275.7 $35 $19,851 $560 $(1,857)(20.5)$(966)$32 $17,655 
Net income25 2 27 
Other Comprehensive (loss) income, after tax(479)(479)
Cash dividends declared(1)
(207)(207)
Stock options/SSARs(2) 1 (1)
Vested restricted stock units and awards(2) 1 (1)
Stock-based compensation18 18 
Other(3)(3)
Balance at September 30, 2023275.7 $35 $19,865 $378 $(2,336)(20.5)$(964)$31 $17,009 

(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)Common
stock		Capital in
excess of
par value		Accumulated deficitAccumulated  other
comprehensive
(loss) income		Treasury stockNon-controlling
interest		Total
SharesCostSharesCost
Balance at July 1, 2024275.7 $35 $19,894 $(2,414)$(2,315)(20.1)$(946)$37 $14,291 
Net income59 1 60 
Other Comprehensive (loss) income, after tax555 555 
Cash dividends declared(1)
(102)(102)
Stock options/SSARs1 0.1 1 2 
Vested restricted stock units and awards(9)  (9)
Stock-based compensation16 16 
Other  (3)(3)
Balance at September 30, 2024275.7 $35 $19,902 $(2,457)$(1,760)(20.0)$(945)$35 $14,810 

(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)Common
stock		Capital in
excess of
par value		Retained
earnings		Accumulated  other
comprehensive
(loss) income		Treasury stockNon-controlling
interest		Total
SharesCostSharesCost
Balance at January 1, 2023275.7 $35 $19,841 $955 $(2,198)(20.8)$(978)$30 $17,685 
Net income43 3 46 
Other Comprehensive (loss) income, after tax(138)(138)
Cash dividends declared(1)
(620)(620)
Stock options/SSARs(5)0.1 4 (1)
Vested restricted stock units and awards(20)0.2 10 (10)
Stock-based compensation50 50 
Purchase of NCI(1)(1)
Other(2)(2)
Balance at September 30, 2023275.7 $35 $19,865 $378 $(2,336)(20.5)$(964)$31 $17,009 


See Notes to Consolidated Financial Statements
3
Table of Contents
(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)Common
stock		Capital in
excess of
par value		Retained
earnings		Accumulated  other
comprehensive
(loss) income		Treasury stockNon-controlling
interest		Total
SharesCostSharesCost
Balance at January 1, 2024275.7 $35 $19,874 $(2,439)$(1,896)(20.4)$(963)$31 $14,642 
Net income289 4 293 
Other Comprehensive (loss) income, after tax136 136 
Cash dividends declared(1)
(306)(306)
Stock options/SSARs(1)0.1 2 1 
Vested restricted stock units and awards(30)0.3 16 (14)
Stock-based compensation59 59 
Other(1) (1)
Balance at September 30, 2024275.7 $35 $19,902 $(2,457)$(1,760)(20.0)$(945)$35 $14,810 
_______________________
(1)Cash dividends declared per common share were $0.40 and $0.81 for the three months ended September 30, 2024 and September 30, 2023, respectively, and $1.20 and $2.43 per share for the nine months ended September 30, 2024 and September 30, 2023, respectively.
See Notes to Consolidated Financial Statements
4
Table of Contents
INTERNATIONAL FLAVORS & FRAGRANCES INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 Nine Months Ended September 30,
(DOLLARS IN MILLIONS)20242023
Cash flows from operating activities:
Net income$293 $46 
Adjustments to reconcile to net cash provided by operating activities
Depreciation and amortization772 855 
Deferred income taxes(128)(59)
Loss on assets classified as held for sale314 — 
Gains on sale of assets(11)(1)
(Gains) Losses on business disposals(348)29 
Stock-based compensation59 50 
Pension contributions(17)(25)
Impairment of goodwill64 — 
Inventory write-down— 62 
Changes in assets and liabilities:
Trade receivables(276)(78)
Inventories(3)489 
Accounts payable(34)(240)
Accruals for incentive compensation119 (40)
Other current payables and accrued expenses65 (216)
Other assets/liabilities, net(167)(77)
Net cash provided by operating activities702 795 
Cash flows from investing activities:
Additions to property, plant and equipment(303)(390)
Additions to intangible assets(5)— 
Proceeds from sale of assets18 22 
Net proceeds received from business disposals876 1,006 
Net cash provided by investing activities586 638 
Cash flows from financing activities:
Cash dividends paid to shareholders(411)(619)
Decrease in revolving credit facility and short-term borrowings— (100)
Net borrowings of commercial paper (maturities less than three months)— (187)
Principal payments of debt(974)(355)
Deferred and contingent consideration paid(36)(6)
Withholding tax paid on stock-based compensation(15)(12)
Other, net(8)(14)
Net cash used in financing activities(1,444)(1,293)
Effect of exchange rate changes on cash, cash equivalents and restricted cash(10)(30)
Net change in cash, cash equivalents and restricted cash(166)110 
Cash, cash equivalents and restricted cash at beginning of year735 552 
Cash, cash equivalents and restricted cash at end of period$569 $662 
Supplemental Disclosures:
Interest paid, net of amounts capitalized$216 $261 
Income taxes paid, net248 450 
Accrued capital expenditures74 67 
See Notes to Consolidated Financial Statements
5
Table of Contents
INTERNATIONAL FLAVORS & FRAGRANCES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1.    NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations
International Flavors & Fragrances Inc. and its subsidiaries (the “Registrant,” “IFF,” “the Company,” “we,” “us” and “our”) is a leading creator and manufacturer of food, beverage, health & biosciences, scent and pharma solutions and complementary adjacent products, including natural health ingredients, which are used in a wide variety of consumer products. Our products are sold principally to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, sweeteners, dietary supplements, food protection, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products.
Basis of Presentation
The accompanying interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the related notes included in our 2023 Annual Report on Form 10-K (“2023 Form 10-K”), filed on February 28, 2024 with the Securities and Exchange Commission (“SEC”).
The interim Consolidated Financial Statements are prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States of America for interim financial information and with the rules and regulations for reporting on Form 10-Q, and are unaudited. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP in the United States of America have been condensed or omitted, if not materially different from the 2023 Form 10-K. The year-end balance sheet data included in this Form 10-Q was derived from the audited financial statements. In the opinion of management, all adjustments, which consist of normal recurring adjustments necessary for a fair statement of the interim Consolidated Financial Statements, have been made.
Correction of Prior Year Consolidated Financial Statements
The Company revised Interest expense from $110 million to $90 million, and Other income, net from $29 million to $9 million, on its Consolidated Statements of Income and Comprehensive Income (Loss) for the three months ended September 30, 2023. The Company also revised Interest expense from $337 million to $291 million and Other income, net from $63 million to $17 million for the nine months ended September 30, 2023. These adjustments had no impact on net income and reflect certain adjustments made to interest expense associated with the Company’s cash pooling arrangements. The impacts of these corrections are also presented in the related footnotes.
Use of Estimates
The preparation of financial statements requires management to make estimates and judgments that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The inputs into the Company’s judgments and estimates take into account the ongoing global current events and adverse macroeconomic impacts on our critical and significant accounting estimates, including estimates associated with future cash flows that are used in assessing the risk of impairment of certain assets. Actual results could differ from those estimates.
Cash, Cash Equivalents and Restricted Cash
Cash, cash equivalents and restricted cash reported in the Company’s balance sheet as of September 30, 2024, December 31, 2023, September 30, 2023 and December 31, 2022 were as follows:
(DOLLARS IN MILLIONS)September 30, 2024December 31, 2023September 30, 2023December 31, 2022
Current assets
Cash and cash equivalents$567 $703 $629 $483 
Cash and cash equivalents included in Assets held for sale2 26 23 52 
Restricted cash— 6 10 10 
Non-current assets
Restricted cash included in Other assets— — — 7 
Cash, cash equivalents and restricted cash$569 $735 $662 $552 
6
Table of Contents
Accounts Receivable
The Company has various factoring agreements globally under which it can factor up to approximately $329 million of its trade receivables (“Company’s own factoring agreements”). In addition, the Company utilizes factoring agreements sponsored by certain customers. Under all of the arrangements, the Company sells the trade receivables on a non-recourse basis to unrelated financial institutions and accounts for the transactions as sales of receivables. The applicable receivables are removed from the Company’s Consolidated Balance Sheets when the cash proceeds are received by the Company.
The Company sold a total of approximately $1,320 million and $1,302 million of receivables under the Company’s own factoring agreements and customer sponsored factoring agreements for the nine months ended September 30, 2024 and 2023, respectively. The cost of participating in these programs was approximately $7 million and $6 million for the three months ended September 30, 2024 and 2023, respectively, and was approximately $21 million and $18 million for the nine months ended September 30, 2024 and 2023, respectively. These costs are included as a component of interest expense. Under the Company’s own factoring agreements for which the Company has continued responsibility to collect receivables and provide to its sponsor, it sold approximately $654 million and $632 million of receivables for the nine months ended September 30, 2024 and 2023, respectively. The outstanding principal amounts of receivables under the Company’s own factoring agreements amounted to approximately $201 million and $196 million as of September 30, 2024 and December 31, 2023, respectively. The proceeds from the sales of receivables are included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows.
Expected Credit Losses
As of September 30, 2024, the Company reported $1.772 billion of trade receivables, net of allowances of $26 million. Based on the aging analysis as of September 30, 2024, less than 1% of the Company’s accounts receivable were past due by over 365 days based on the payment terms of the invoice.
The following is a roll-forward of the Company’s allowances for bad debts for the nine months ended September 30, 2024 and 2023.
Nine Months Ended September 30,
(DOLLARS IN MILLIONS)20242023
Balance at January 1$52 $53 
Bad debt expense (reversals)(8)9
Write-offs(17)(6)
Foreign exchange (gains) losses(1)(1)
Balance at September 30$26 $55 
Inventories
Inventories are stated at the lower of cost (on a weighted-average basis) or net realizable value. The Company’s inventories consisted of the following:
(DOLLARS IN MILLIONS)September 30, 2024December 31, 2023
Raw materials$727 $779 
Work in process384 406 
Finished goods1,089 1,292 
Total$2,200 $2,477 
Supply Chain Financing Program
In the fourth quarter of 2023, the Company entered into a supply chain financing (“SCF”) program. The SCF program is expected to be available to U.S. based suppliers starting in the fourth quarter of 2024. The Company makes continuous efforts to improve working capital efficiency and has worked with suppliers to optimize payment terms and conditions. The Company’s current payment terms with a majority of suppliers range from 0 to 180 days, which the Company believes is consistent with commercial practice. The Company’s SCF program is voluntary and will allow its suppliers to elect to sell the receivables owed to them by the Company to a third-party financial institution. The suppliers, at their own discretion, will determine the invoices they want to sell and directly negotiate the arrangements with the participating third-party financial institution. Supplier participation in the program is solely the decision of the supplier and has no bearing on the Company’s payment terms and amounts due with the supplier. The Company’s responsibility will be limited to making payments based upon the agreed contractual terms and arrangements. The Company will not provide any form of guarantees under the SCF program and will have no economic interest in the suppliers’ decision to participate in the SCF program. Amounts due to
7
Table of Contents
suppliers that elect to participate in the SCF program will be included in Accounts payable on the Consolidated Balance Sheets. The Company, or the third-party financial institution, may choose to terminate the agreement of the SCF program at any time upon 30 days’ prior written notice. The third-party financial institution may also terminate the agreement of the SCF program at any time upon three business days’ prior written notice in the event there are insufficient funds available for disbursements. As of September 30, 2024 and December 31, 2023, there were no amounts outstanding related to suppliers’ participation in the SCF program.
Recent Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The ASU was issued to further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. This guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the impact that this guidance will have on its income tax disclosures.

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The ASU intends to improve reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses that are regularly provided to the Chief Operating Decision Maker and included within segment profit and loss. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and applied retrospectively to all prior periods presented in the financial statements. The Company expects that the adoption of the standard will impact certain segment reporting disclosures in the Notes to the Consolidated Financial Statements, but will otherwise not have a material impact on the Company's results of operations.

NOTE 2. NET INCOME PER SHARE
A reconciliation of the shares used in the computation of basic and diluted net income per share is as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)2024202320242023
Net Income
Net income attributable to IFF shareholders$59 $25 $289 $43 
Adjustment related to (increase) in redemption value of redeemable non-controlling interests in excess of earnings allocated— — — (1)
Net income available to IFF shareholders$59 $25 $289 $42 
Shares
Weighted average common shares outstanding (basic)256 255 255 255 
Adjustment for assumed dilution:
Stock options and restricted stock awards1 1 1 — 
Weighted average shares assuming dilution (diluted)257 256 256 255 
Net Income per Share
Net income per share - basic and diluted$0.23 $0.10 $1.13 $0.16 
The Company declared a quarterly dividend to its shareholders of $0.40 and $0.81 per share for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, the Company declared quarterly dividends to its shareholders totaling $1.20 and $2.43, respectively.
For the three and nine months ended September 30, 2024, there were approximately 0.3 million share equivalents that had an anti-dilutive effect and therefore were excluded from the computation of diluted net income per share in the period. For the three and nine months ended September 30, 2023, there were approximately 0.4 million share equivalents that had an anti-dilutive effect and therefore were excluded from the computation of diluted net loss per share.
The Company has issued shares of Purchased Restricted Stock Units (“PRSUs”) which contain rights to non-forfeitable dividends while these shares are outstanding and thus are considered participating securities. Such securities are required to be included in the computation of basic and diluted earnings per share pursuant to the two-class method.
8
Table of Contents
The Company did not present the two-class method since the difference between basic net income per share for both unrestricted common shareholders and PRSU shareholders for the three and nine months ended September 30, 2024 and 2023 was less than $0.01 per share.

NOTE 3. BUSINESS DIVESTITURES AND ASSETS AND LIABILITIES HELD FOR SALE
Divestiture of the Cosmetic Ingredients Business
During the third quarter of 2023, the Company announced it had entered into an agreement to sell its Cosmetic Ingredients business, which was a part of the Scent segment. The Company completed the divestiture on April 2, 2024, and received cash proceeds of approximately $841 million. The sale consideration is subject to certain post-closing adjustments, which is primarily related to cash, indebtedness and working capital balances.
The following table summarizes the fair value of sale consideration received in connection with the business divestiture:
(DOLLARS IN MILLIONS)
Cash proceeds from the buyer$841 
Direct costs to sell(10)
Fair value of sale consideration$831 
The Net proceeds received from business disposals presented under Cash flows from investing activities represent the cash portion of the sale consideration, which was determined as the fair value of sale consideration adjusted by the cash transferred to the buyer as part of the transaction. Amounts paid for direct costs to sell are presented under Cash flows from operating activities. The following table summarizes the different components of Net proceeds received from business disposals presented under Cash flows from investing activities:
(DOLLARS IN MILLIONS)
Cash proceeds from the buyer$841 
Cash transferred to the buyer(32)
Net Cash flows from investing activities$809 
The carrying amount of net assets associated with the business unit, adjusted for currency translation adjustment, was approximately $466 million. The major classes of assets and liabilities sold consisted of the following:
9
Table of Contents
(DOLLARS IN MILLIONS)April 2, 2024
Assets
Cash and cash equivalents$32 
Trade receivables, net18 
Inventories17 
Property, plant and equipment, net7 
Goodwill271 
Other intangible assets, net144 
Operating lease right-of-use assets10 
Other assets11 
Total assets510 
Liabilities
Accounts payable$(5)
Deferred tax liability(25)
Other liabilities(18)
Total liabilities(48)
Equity
Accumulated other comprehensive income - currency translation adjustment4 
Total equity4 
Carrying value of net asset (adjusted for currency translation adjustment)$466 
As a result of the business divestiture, the Company recognized a pre-tax gain of approximately $365 million, subject to certain post-closing adjustments, presented in (Gains) losses on business disposals on the Consolidated Statements of Income and Comprehensive Income (Loss) for the nine months ended September 30, 2024. The total income tax expense/(benefit) recognized was approximately $34 million, with approximately $(7) million that was recognized during the year ended December 31, 2023.
Divestiture of the Flavors and Essences UK Business
During the third quarter of 2024, the Company completed the divestiture of its Flavors and Essences UK (“F&E”) business, which was a part of the Nourish segment. The Company completed the divestiture on September 1, 2024, and received net cash proceeds of approximately $28 million. The carrying amount of net assets associated with the business unit, adjusted for currency translation adjustment, was approximately $48 million. The majority of net assets sold included intangible assets and goodwill attributable to the F&E business. As part of the business divestiture, the Company recognized a pre-tax loss of approximately $20 million presented in (Gains) losses on business disposals and a tax benefit of approximately $1 million presented in Provision for income taxes on the Consolidated Statements of Income and Comprehensive Income (Loss) for the three and nine months ended September 30, 2024.
Divestiture of the Flavors Specialty Ingredients Business
The Company completed the divestiture of the Flavors Specialty Ingredients business on August 1, 2023, and received net cash proceeds of approximately $185 million, which included $1 million related to the delayed transfer of the control of specific assets and liabilities of non-U.S. jurisdiction business. In addition, approximately $15 million of proceeds were held in escrow and were released upon satisfaction of certain conditions during the fourth quarter of 2023. Concurrent with the completion of the business divestiture, the Company entered into a supply agreement with the buyer. Based on the terms of the supply agreement, an adjustment of $4 million was made against the fair value of sale consideration.
As a result of the business divestiture, the Company recognized a pre-tax loss of approximately $10 million presented in (Gains) losses on business disposals on the Consolidated Statements of Income and Comprehensive Income (Loss) for the three and nine months ended September 30, 2023. There was a net working capital adjustment of $(3) million for the nine months ended September 30, 2024, resulting in a cumulative pre-tax loss of approximately $7 million.
Divestiture of a Portion of the Savory Solutions Business
10
Table of Contents
The Company completed the divestiture of a Portion of the Savory Solutions business on May 31, 2023, and received net cash proceeds of approximately $821 million. In addition, a receivable of approximately $37 million was recorded which reflected the remaining sale consideration that was received in January 2024.
As a result of the divestiture, the Company recognized a pre-tax loss of approximately $10 million presented in (Gains) losses on business disposals on the Consolidated Statements of Income and Comprehensive Income (Loss) for the nine months ended September 30, 2023. There was a net working capital adjustment of $7 million for the three months ended December 31, 2023, resulting in a cumulative pre-tax loss of approximately $3 million.
Liquidation of a Business in Russia
As part of the liquidation of a business in Russia for the sale of the portion of the Savory Solutions business, the Company recognized a pre-tax loss of approximately $10 million presented in the (Gains) losses on business disposals, and tax benefits of approximately $2 million presented in Provision for income taxes on the Consolidated Statements of Income and Comprehensive Income (Loss) for the nine months ended September 30, 2023.
Assets and Liabilities Held for Sale
Pharma Solutions
During the first quarter of 2024, the Company announced it had entered into an agreement to sell its Pharma Solutions business, that is primarily made up of most businesses within the Company's existing Pharma Solutions reportable operating segment as well as certain adjacent businesses (the “Pharma Solutions disposal group”). The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2025.
The sale does not constitute a strategic shift of the Company’s operations and does not, and will not, have major effects on the Company’s operations and financial results. Therefore, the transaction does not meet the discontinued operations criteria.
The Company determined that the assets and liabilities of the Pharma Solutions disposal group met the criteria to be presented as “held for sale” during the second quarter of 2024. As a result, at September 30, 2024, such assets and liabilities were classified as held for sale on the Consolidated Balance Sheets.
The classification of the Pharma Solutions disposal group as held for sale was considered an event or change in circumstance which required an assessment of the existing Pharma Solutions reporting unit. The Company performed a pre-classification goodwill impairment test and determined that the fair value of the Pharma Solutions reporting unit exceeded the carrying value.
The Company engaged an independent third party to determine the fair value of the assets held for sale as of May 1, 2024, based upon the sale price including earn outs expected to be received from the buyer. The fair value of the earn out was based on a Monte Carlo simulation. Goodwill was allocated to the Pharma Solutions disposal group based upon the relative fair value of the businesses included in the disposal group compared to the reporting units to which the businesses relate. The Company then performed a post-classification goodwill impairment test and determined that the fair value was less than the carrying value of the Pharma Solutions disposal group. As such, the Company recorded a non-cash goodwill impairment charge of $64 million which is presented in Impairment of goodwill on the Consolidated Statements of Income and Comprehensive Income (Loss) for the nine months ended September 30, 2024.
The Company also performed a goodwill impairment test of the remaining businesses in the Pharma Solutions reporting unit that were not classified as held for sale and determined that the fair value exceeded the carrying value.
At September 30, 2024, the Company engaged an independent third-party to determine an updated fair value of the Pharma Solutions disposal group. The Company determined that the fair value of $2,708 million (fair value of $2,740 million less estimated costs to sell of $32 million) of the Pharma Solutions disposal group was less than the carrying value. As such, the Company recorded a loss in the third quarter of 2024 of $22 million to adjust the carrying value of the disposal group to its fair value less cost to sell, bringing the total year-to-date loss to $304 million. This is presented in Loss on assets classified as held for sale on the Consolidated Statements of Income and Comprehensive Income (Loss) for the three and nine months ended September 30, 2024. The Company recorded the loss on classification of held for sale as a valuation allowance on the group of assets held for sale, without allocation to the individual assets or major classes of assets within the group.
For the nine months ended September 30, 2024, the Company recognized total income tax benefits of $62 million related to loss on assets classified as held for sale for the Pharma Solutions disposal group.

In addition, pursuant to the terms agreed under the 2026 Term Loan Facility, a portion of the net cash proceeds received from the sale of the Pharma Solutions disposal group, when and if completed, must be used to repay our borrowings under the 2026 Term Loan Facility. Therefore, the Company reclassified the 2026 Term Loan Facility balance from “Long-term debt” to “Short-term debt and current portion of long-term debt” (see Note 13).

Nitrocellulose
11
Table of Contents
During October of 2024, the Company entered into an agreement to sell its nitrocellulose business (including the related industrial park in Germany), which is within the Company's existing Pharma Solutions reportable operating segment. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2025.
The Company determined that the assets and liabilities of the nitrocellulose business met the criteria to be presented as “held for sale” during the third quarter of 2024. As a result, as of September 30, 2024, such assets and liabilities were classified as held for sale on the Consolidated Balance Sheets. The Company determined that, as of September 30, 2024, the fair value less estimated costs to sell of the nitrocellulose business exceeded the underlying carrying value.
The sale does not constitute a strategic shift of the Company’s operations and does not, and will not, have major effects on the Company’s operations and financial results. Therefore, the transaction does not meet the discontinued operations criteria.
Portion of the Savory Solutions Business in Turkey
During the third quarter of 2024, the Company entered into an agreement to sell assets of the Savory Solutions business in Turkey. The transaction is expected to close in the first quarter of 2025. The Company has determined that the assets meet the criteria to be held for sale as of September 30, 2024. The Company recorded a loss of $10 million in the third quarter of 2024 to adjust the carrying value of the assets to its fair value based on the agreed sales price. This is presented in Loss on assets classified as held for sale on the Consolidated Statements of Income and Comprehensive Income (Loss) for the three and nine months ended September 30, 2024. The Company recognized total income tax benefits of $1 million related to loss on assets classified as held for sale for the portion of the Savory Solutions business in Turkey.
Carrying Amount of Assets and Liabilities Held for Sale
As of December 31, 2023, the assets and liabilities of the Cosmetic Ingredients business met the criteria to be presented as “held for sale”. The Company completed the divestiture on April 2, 2024 and therefore the assets and liabilities of the Cosmetic Ingredients business are not included in the Company's Consolidated Balance Sheets as of September 30, 2024.
Included in the Company’s Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 are the following carrying amounts of the assets and liabilities held for sale:
(DOLLARS IN MILLIONS)September 30, 2024December 31, 2023
Assets
Cash and cash equivalents$2 $26 
Trade receivables, net195 15 
Inventories286 18 
Property, plant and equipment, net438 7 
Goodwill(1)
1,264 276 
Other intangible assets, net1,119 146 
Operating lease right-of-use assets15 9 
Other assets109 9 
Less: Loss recognized on assets held-for-sale(2)
(314)— 
Total assets held-for-sale$3,114 $506 
Liabilities
Accounts payable$83 $4 
Deferred tax liability63 24 
Other liabilities158 18 
Total liabilities held-for-sale$304 $46 
_______________________
(1)The goodwill balance in assets held for sale for the Pharma Solutions disposal group as of September 30, 2024, is presented net of $64 million of goodwill impairment.
(2)Includes the impact of $51 million, primarily related to losses on foreign currency translation, expected to be reclassified out of accumulated other comprehensive loss upon close of the sales.

NOTE 4.    RESTRUCTURING AND OTHER CHARGES
Restructuring and other charges primarily consist of separation costs for employees including severance, outplacement and other employee benefit costs (“Severance”), charges related to the write-down of fixed assets of plants to be closed (“Fixed asset write-down”) and all other related restructuring (“Other”) costs. All restructuring and other charges are separately stated on the Consolidated Statements of Income and Comprehensive Income (Loss).
12
Table of Contents
N&B Merger Restructuring Liability
For the three and nine months ended September 30, 2024, the Company had no charges related to severance. For the nine months ended September 30, 2024, the Company had approximately $2 million of charges related to a lease impairment. For the three and nine months ended September 30, 2023, the Company had approximately $3 million and $2 million of charges, respectively. Since the inception of the restructuring activities, there have been a total of approximately 215 headcount reductions and the Company has expensed approximately $49 million. As of December 31, 2023, the restructuring activities were completed related to employee exits. The Company continues to evaluate its owned and leased properties following the combination of IFF and DuPont de Nemours, Inc’s nutrition and biosciences business (“Merger with N&B”) and may incur additional costs to further consolidate its footprint.
2023 Restructuring Program
In December 2022, the Company announced a restructuring program mainly related to headcount reduction to improve its organizational and operating structure, drive efficiencies and achieve cost savings. For the three and nine months ended September 30, 2024, the Company incurred approximately $1 million and $4 million of charges related to severance, respectively. For the three and nine months ended September 30, 2023, the Company incurred approximately $1 million of reversals and $63 million of charges related to severance, respectively. Since the inception of the restructuring program, the Company has expensed approximately $74 million and there have been a total of approximately 670 actual headcount reductions.
Changes in Restructuring Liabilities
Changes in restructuring liabilities during the nine months ended September 30, 2024 were as follows:
(DOLLARS IN MILLIONS)
Balance at
January 1, 2024
Additional Charges (Reversals), NetNon-Cash ChargesCash Payments
Balance at
September 30, 2024
N&B Merger Restructuring Liability
Other$— $2 $(2)$— $— 
2023 Restructuring Program
Severance14 4 — (16)2 
Total Restructuring and other charges$14 $6 $(2)$(16)$2 
Restructuring liabilities are presented in “Other current liabilities” on the Consolidated Balance Sheets.
Charges by Segment
The following table summarizes the total amount of costs incurred in connection with the restructuring programs and activities by segment.
 Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2024202320242023
Nourish$— $1 $3 $33 
Health & Biosciences— 1 1 12 
Scent— — 1 14 
Pharma Solutions1 — 1 2 
Total Restructuring and other charges$1 $2 $6 $61 

NOTE 5.    STOCK COMPENSATION PLANS
The Company has various plans under which its officers, senior management, other key employees and directors may be granted equity-based awards. Equity awards outstanding under the plans include PRSUs, Restricted Stock Units (“RSUs”), Stock-Settled Appreciation Rights (“SSARs”) and Long-Term Incentive Plan awards. Liability-based awards outstanding under the plans are cash-settled RSUs.
13
Table of Contents
Stock-based compensation expense and related tax benefits were as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2024202320242023
Equity-based awards$16 $18 $59 $50 
Liability-based awards1 — 3 — 
Total stock-based compensation expense17 18 62 50 
Less: Tax benefit(3)(5)(12)(11)
Total stock-based compensation expense, after tax$14 $13 $50 $39 
As of September 30, 2024, there was approximately $96 million of total unrecognized compensation cost related to non-vested awards granted under the equity incentive plans.

NOTE 6. SEGMENT INFORMATION
The Company is organized into four reportable operating segments: Nourish, Health & Biosciences, Scent and Pharma Solutions.
Reportable segment information was as follows:
 Three Months EndedNine Months Ended
September 30,September 30,
(DOLLARS IN MILLIONS)2024202320242023
Net sales:
Nourish$1,486 $1,449 $4,460 $4,666 
Health & Biosciences570 518 1,659 1,553 
Scent613 615 1,861 1,815 
Pharma Solutions256 238 733 742 
Consolidated$2,925 $2,820 $8,713 $8,776 
Segment Adjusted Operating EBITDA:
Nourish$206 $178 $654 $567 
Health & Biosciences173 150 497 426 
Scent127 131 421 353 
Pharma Solutions62 47 162 173 
Total568 506 1,734 1,519 
Depreciation & Amortization(248)(292)(772)(855)
Interest Expense(74)(90)(236)(291)
Other (Expense) Income, net(28)9 (44)17 
Restructuring and Other Charges a)(1)(2)(6)(61)
Impairment of Goodwill b)— — (64)— 
Gains (Losses) on Business Disposals c)(20)(10)348 (29)
Loss on Assets Classified as Held for Sale d)(32)— (314)— 
Acquisition, Divestiture and Integration Costs e)(55)(42)(172)(118)
Strategic Initiatives Costs f)(6)(6)(22)(28)
Regulatory Costs g)(10)(13)(64)(32)
Other h)1 (1)5 1 
Income Before Taxes$95 $59 $393 $123 
_______________________
a)For 2024, represents costs related to lease impairment and severance as part of the Company's restructuring efforts. For 2023, represents costs primarily related to severance as part of the Company's restructuring efforts.
b)For 2024, represents costs related to the impairment of goodwill related to the Pharma Solutions disposal group.
14
Table of Contents
c)
For 2024, primarily represents gains recognized as part of the sale of the Cosmetic Ingredients business and losses recognized as part of the sale of the F&E UK business. For 2023, primarily represents losses recognized as part of the sale of the Flavors Specialty Ingredients business, the sale of a portion of the Savory Solutions business, and liquidation of a business in Russia for the sale of the portion of the Savory Solutions business.
d)For 2024, represents the losses recognized on assets classified as held for sale of the Pharma Solutions disposal group and portion of the Savory Solutions business in Turkey.
e)
For 2024 and 2023, primarily represents costs related to the Company's actual and planned acquisitions and divestitures and integration related activities primarily for N&B. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.

For the three months ended September 30, 2024, business divestiture costs were approximately $55 million. For the three months ended September 30, 2023, business divestiture, integration and acquisition costs were approximately $29 million, $12 million and $1 million, respectively. For the nine months ended September 30, 2024, business divestiture and integration costs were approximately $167 million and $5 million, respectively. For the nine months ended September 30, 2023, business divestiture, integration and acquisition costs were approximately $70 million, $42 million, and $6 million, respectively.
f)Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services Centers, primarily consulting fees.
g)Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.
h)Represents gains (losses) from sale of assets, executive employee separation costs and costs related to the Company's entity realignment project to optimize the structure of holding companies, primarily consulting fees.
Net sales, which are attributed to individual regions based upon the destination of product delivery, were as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2024202320242023
Europe, Africa and Middle East$964 $918 $2,913 $2,958 
Greater Asia694 670 2,057 2,031 
North America886 853 2,628 2,668 
Latin America381 379 1,115 1,119 
Consolidated$2,925 $2,820 $8,713 $8,776 
 Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2024202320242023
Net sales related to the U.S.$834 $782 $2,467 $2,430 
Net sales attributed to all foreign countries2,091 2,038 6,246 6,346 
No non-U.S. country had net sales greater than 10% of total consolidated net sales for each of the three and nine months ended September 30, 2024 and 2023.

NOTE 7. EMPLOYEE BENEFITS
Pension and other defined contribution retirement plan expenses included the following components:
(DOLLARS IN MILLIONS)U.S. Plans
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Interest cost on projected benefit obligation(2)
$6 $6 $17 $19 
Expected return on plan assets(2)
(6)(7)(18)(23)
Net amortization and deferrals(2)
1 — 3 1 
Net periodic benefit (income) cost$1 $(1)$2 $(3)
15
Table of Contents
(DOLLARS IN MILLIONS)Non-U.S. Plans
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Service cost for benefits earned(1)
$6 $5 $18 $15 
Interest cost on projected benefit obligation(2)
9 9 27 27 
Expected return on plan assets(2)
(13)(11)(38)(34)
Net amortization and deferrals(2)
2 — 5 (1)
Net periodic benefit (income) cost$4 $3 $12 $7 
_______________________
(1)Included as a component of Operating profit.
(2)Included as a component of Other expense (income), net.
The Company expects to contribute a total of $5 million to its U.S. pension plans and a total of $23 million to its non-U.S. pension plans during 2024. During the nine months ended September 30, 2024, $1 million of contributions were made to the qualified U.S. pension plans, $14 million of contributions were made to the non-U.S. pension plans and $3 million of contributions were made with respect to the Company’s non-qualified U.S. pension plan.
(Income) expense recognized for post-retirement benefits other than pensions included the following components:
 Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2024202320242023
Interest cost on projected benefit obligation$1 $— $2 $2 
Net amortization and deferrals(1)(1)(2)(4)
Total postretirement benefit (income) expense$— $(1)$— $(2)
The Company expects to make $4 million of payments related to its postretirement benefits other than pension plans during 2024. In the nine months ended September 30, 2024, $2 million of benefit payments were made.

NOTE 8. OTHER (EXPENSE) INCOME, NET
Other (expense) income, net consisted of the following:
 Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2024202320242023
Foreign exchange losses$(31)$— $(72)$(34)
Interest income3 1 9 3 
Gain on China facility relocation— — — 22 
Pension-related benefit1 6 4 16 
Other(1)2 15 10 
Other (expense) income, net$(28)$9 $(44)$17 

NOTE 9. INCOME TAXES
The effective tax rate for the three months ended September 30, 2024 was 36.8%, which was primarily driven by tax impacts on business divestitures and changes in the mix of earnings, some of which do not give rise to tax benefits due to valuation allowances.
The effective tax rate for the nine months ended September 30, 2024 was 25.4%, which was primarily driven by tax impacts on business divestitures and changes in the mix of earnings, some of which do not give rise to tax benefits due to valuation allowances.    
As of September 30, 2024, the Company had approximately $128 million of unrecognized tax benefits recorded in Other liabilities. If these unrecognized tax benefits were recognized, the effective tax rate would be affected.
16
Table of Contents
As of September 30, 2024, the Company had accrued interest and penalties of approximately $54 million classified in Other liabilities.
As of September 30, 2024, the Company’s aggregate provisions for uncertain tax positions, including interest and penalties, was approximately $182 million associated with tax positions asserted in various jurisdictions.
The Company regularly repatriates earnings from non-U.S. subsidiaries. As the Company repatriates these funds to the U.S., there will be required income taxes payable in certain U.S. states and applicable foreign withholding taxes during the period when such repatriation occurs. Accordingly, as of September 30, 2024, the Company had a deferred tax liability of approximately $167 million for the effect of repatriating the funds to the U.S., attributable to various non-U.S. subsidiaries. There is no deferred tax liability associated with non-U.S. subsidiaries where the Company intends to indefinitely reinvest the earnings to fund local operations and/or capital projects.

NOTE 10. PROPERTY, PLANT AND EQUIPMENT, NET
Property, plant and equipment consisted of the following amounts:
(DOLLARS IN MILLIONS)September 30, 2024December 31, 2023
Asset Type
Land$142 $195 
Buildings and improvements1,747 1,822 
Machinery and equipment3,527 3,752 
Information technology527 473 
Construction in process323 400 
Total Property, plant and equipment6,266 6,642 
Accumulated depreciation(2,494)(2,402)
Total Property, plant and equipment, net$3,772 $4,240 
Depreciation expense was $102 million and $122 million for the three months ended September 30, 2024 and 2023, respectively, and $305 million and $342 million for the nine months ended September 30, 2024 and 2023, respectively.
Interest incurred during the construction period of certain property, plant and equipment is capitalized until the underlying assets are placed in service, at which time straight-line amortization of the capitalized interest begins over the estimated useful lives of the related assets. Capitalized interest was approximately $3 million and $4 million for the three months ended September 30, 2024 and 2023, and approximately $10 million and $13 million for the nine months ended September 30, 2024 and 2023.

NOTE 11. GOODWILL AND OTHER INTANGIBLE ASSETS, NET
Goodwill
Movements in goodwill attributable to each reportable segment for the nine months ended September 30, 2024 were as follows:
(DOLLARS IN MILLIONS)NourishHealth & BiosciencesScentPharma SolutionsTotal
Balance at January 1, 2024$3,489 $4,391 $1,490 $1,265 $10,635 
Transferred to assets held for sale(1)
(55)— — (1,248)(1,303)
Reduction from business divestitures(2)
(10)— — — (10)
Foreign exchange20 20 4 (17)27 
Balance at September 30, 2024$3,444 $4,411 $1,494 $— $9,349 
_______________________
(1)Recognized $64 million of impairment related to the Pharma Solutions disposal group classified as held for sale as of September 30, 2024. See Note 3 for additional information.
(2)Relates to the divestiture of the Flavors & Essences UK business. See Note 3 for additional information.
The goodwill balances at January 1, 2024 and September 30, 2024 included $2.623 billion and $2.250 billion of accumulated impairment related to the Nourish and Health & Biosciences reportable segments. The accumulated impairment relates to impairment charges recorded in 2023 and 2022.
17
Table of Contents
Other Intangible Assets
Other intangible assets, net consisted of the following amounts:
September 30,December 31,
(DOLLARS IN MILLIONS)20242023
Asset Type
Customer relationships$7,209 $8,211 
Technological know-how1,992 2,355 
Trade names & patents277 337 
Other25 44 
Total carrying value 9,503 10,947 
Accumulated Amortization
Customer relationships(1,733)(1,619)
Technological know-how(853)(813)
Trade names & patents(126)(117)
Other(21)(41)
Total accumulated amortization(2,733)(2,590)
Other intangible assets, net$6,770 $8,357 
Amortization
Amortization expense was $146 million and $170 million for the three months ended September 30, 2024 and 2023, respectively, and $467 million and $513 million for the nine months ended September 30, 2024 and 2023, respectively.
Amortization expense for the next five years, based on valuations and determinations of useful lives, is expected to be as follows:
(DOLLARS IN MILLIONS)Remainder of 20242025202620272028
Estimated future intangible amortization expense$146 $583 $580 $493 $480 

NOTE 12.    OTHER CURRENT ASSETS AND LIABILITIES, AND OTHER ASSETS
Prepaid expenses and other current assets consisted of the following amounts:
(DOLLARS IN MILLIONS)September 30, 2024December 31, 2023
Value-added tax receivable$163 $187 
Prepaid income taxes126 178 
Packaging materials and supplies135 161 
Prepaid expenses229 184 
Other117 165 
Total$770 $875 
Other assets consisted of the following amounts:
(DOLLARS IN MILLIONS)September 30, 2024December 31, 2023
Deferred income taxes$401 $278 
Overfunded pension plans129 139 
Cash surrender value of life insurance contracts52 49 
Finance lease right-of-use assets28 26 
Equity method investments10 11 
Other(1)
348 261 
Total$968 $764 
_______________________
(1)Includes long-term receivables, deposits, land usage rights in China, and derivative assets.

Other current liabilities consisted of the following amounts:
18
Table of Contents
(DOLLARS IN MILLIONS)September 30, 2024December 31, 2023
Rebates and incentives payable$123 $105 
Value-added tax payable56 77 
Interest payable70 65 
Current pension and other postretirement benefit obligation13 13 
Earn outs payable(1)
— 32 
Accrued restructuring2 14 
Current operating lease obligation88 85 
Accrued income taxes67 194 
Accrued expenses payable(1)
251 295 
Other81 97 
Total$751 $977 
_______________________ 
(1)During the nine months ended September 30, 2024, the Company paid $36 million to the Seller as part of the acquisition of Health Wright Products, Inc., out of which $30 million related to “Earn outs payable”, and $6 million related to escrow funds which were recorded within “Accrued expenses payable”.

NOTE 13.    DEBT
Debt consisted of the following:
(DOLLARS IN MILLIONS)Effective Interest RateSeptember 30, 2024December 31, 2023
2024 Euro Notes(1)
1.88 %$— $552 
2025 Notes(1)
1.22 %1,000 1,000 
2026 Euro Notes(1)
1.93 %892 879 
2027 Notes(1)
1.56 %1,210 1,212 
2028 Notes(1)
4.57 %398 398 
2030 Notes(1)
2.21 %1,508 1,508 
2040 Notes(1)
3.04 %772 773 
2047 Notes(1)
4.44 %494 495 
2048 Notes(1)
5.12 %787 787 
2050 Notes(1)
3.21 %1,568 1,569 
2024 Term Loan Facility(1)
3.75 %— 270 
2026 Term Loan Facility(1)
5.21 %468 625 
Revolving Credit Facility(2)
— — 
Commercial paper(3)
— — 
Bank overdrafts and other2 3 
Total debt9,099 10,071 
Less: Short-term borrowings(4)
(468)(885)
Total Long-term debt$8,631 $9,186 
_______________________ 
(1)Amount is net of unamortized discount and debt issuance costs.
(2)The interest rate on the Revolving Credit Facility is, at the applicable borrower’s option, a per annum rate equal to either (x) an eurocurrency rate plus an applicable margin varying from 1.125% to 1.750% or (y) a base rate plus an applicable margin varying from 0.125% to 0.750%, in each case depending on the public debt ratings for non-credit enhanced long-term senior unsecured debt issued by the Company.
(3)The effective interest rate of commercial paper issuances fluctuates as short-term interest rates and demand fluctuate, and deferred debt issuance costs are immaterial. Additionally, the effective interest rate of commercial paper is not meaningful as issuances do not materially differ from short-term interest rates.
(4)Includes current portion of long-term debt, commercial paper, and overdrafts.
19
Table of Contents
Commercial Paper
For the nine months ended September 30, 2024, the Company had gross issuances of $3.653 billion and repayments of $3.653 billion under the commercial paper program. The commercial paper issued had original maturities of less than 42 days. For the nine months ended September 30, 2023, the Company had gross issuances of $4.283 billion and repayments of $4.470 billion under the commercial paper program. The commercial paper issued had original maturities of less than 86 days.
The commercial paper program is backed by the borrowing capacity available under the Revolving Credit Facility. The effective interest rate of commercial paper issuances does not materially differ from short-term interest rates, which fluctuate due to market conditions and as a result may impact our interest expense.
Revolving Credit Facility
For the nine months ended September 30, 2024, the Company had drawdowns of $250 million under the Revolving Credit Facility and repayments of $250 million under the Revolving Credit Facility. For the nine months ended September 30, 2023, the Company had drawdowns of $800 million and repayments of $900 million under the Revolving Credit Facility.
Term Loan Facility
Pursuant to the terms agreed under the 2026 Term Loan Facility, a portion of the net cash proceeds received from the sale of the Pharma Solutions disposal group, when and if completed, must be used to repay our borrowings under the 2026 Term Loan Facility. Therefore, the Company reclassified the 2026 Term Loan Facility balance from “Long-term debt” to “Short-term debt and current portion of long-term debt” (see Note 3).
Repayments of Debt
For the nine months ended September 30, 2024, the Company made a $270 million and €500 million (approximately $547 million) debt repayment at maturity related to the 2024 Term Loan Facility and 2024 Euro Notes, respectively, which were primarily funded from commercial paper issuances, which were subsequently repaid using proceeds received from the divestiture of the Cosmetic Ingredients business. The Company also made quarterly debt repayments totaling approximately $47 million related to the 2026 Term Loan Facility in accordance with the terms of the debt agreement, and a voluntary repayment of $110 million related to the 2026 Term Loan Facility.
For the nine months ended September 30, 2023, the Company made a $300 million debt repayment related to the 2023 Notes at maturity, which was funded from the issuance of $400 million under the Revolving Credit Facility. The issuance under the Revolving Credit Facility was repaid in June 2023. The Company also made a voluntary $55 million debt repayment related to the 2024 Term Loan Facility.

NOTE 14.   LEASES
The Company has leases for corporate offices, manufacturing facilities, research and development facilities and certain transportation and office equipment. The Company’s leases have remaining lease terms of up to 50 years, some of which include options to extend the leases for up to 15 years.
The components of lease expense were as follows:
Three Months EndedThree Months EndedNine Months EndedNine Months Ended
(DOLLARS IN MILLIONS)September 30, 2024September 30, 2023September 30, 2024September 30, 2023
Operating leases
Operating lease cost$31 $32 $95 $105 
Variable lease cost14 10 42 42 
Total operating lease cost$45 $42 $137 $147 
Finance leases
Finance lease cost$3 $3 $9 $7 
20
Table of Contents
Supplemental cash flow information related to leases was as follows:
Nine Months EndedNine Months Ended
(DOLLARS IN MILLIONS)September 30, 2024September 30, 2023
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$90 $94 
Operating cash flows for finance leases1 1 
Financing cash flows for finance leases7 6 
Right-of-use assets obtained in exchange for lease obligations
Operating leases44 73 
Finance leases12 17 
Operating lease right-of-use assets are presented in “Operating lease right-of-use assets” and finance lease right-of-use assets are presented in “Other assets” on the Consolidated Balance Sheets. Operating lease liabilities are presented in “Operating lease liabilities” and finance lease liabilities are presented in “Other liabilities” on the Consolidated Balance Sheets. Any other current liabilities related to operating and finance lease liabilities are presented in “Other current liabilities” on the Consolidated Balance Sheets.

NOTE 15. FINANCIAL INSTRUMENTS
Fair Value
Accounting guidance on fair value measurements specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs create the following fair value hierarchy:
•Level 1 — Quoted prices for identical instruments in active markets.
•Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.
•Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company also considers counterparty credit risk in its assessment of fair value. The Company determines the fair value of structured liabilities (where performance is linked to structured interest rates, inflation or currency risks) using the Secured Overnight Financing Rate (“Term SOFR”) swap curve and forward interest and exchange rates at period end. Such instruments are classified as Level 2 based on the observability of significant inputs to the model. The Company does not have any instruments classified as Level 3, other than those included in pension asset trusts as discussed in Note 15 of the Company’s 2023 Form 10-K.
21
Table of Contents
The carrying values and the estimated fair values of financial instruments at September 30, 2024 and December 31, 2023 consisted of the following:
 September 30, 2024December 31, 2023
(DOLLARS IN MILLIONS)Carrying ValueFair ValueCarrying ValueFair Value
LEVEL 1
Cash and cash equivalents(1)
$567 $567 $703 $703 
LEVEL 2
Credit facilities and bank overdrafts(2)
2 2 3 3 
Derivatives
Derivative assets(3)
57 57 41 41 
Derivative liabilities(3)
167 167 165 165 
Commercial paper(2)
— — — — 
Long-term debt:
2024 Euro Notes(4)
— — 552 549 
2025 Notes(4)
1,000 966 1,000 924 
2026 Euro Notes(4)
892 873 879 835 
2027 Notes(4)
1,210 1,112 1,212 1,049 
2028 Notes(4)
398 402 398 389 
2030 Notes(4)
1,508 1,316 1,508 1,240 
2040 Notes(4)
772 575 773 536 
2047 Notes(4)
494 421 495 382 
2048 Notes(4)
787 736 787 678 
2050 Notes(4)
1,568 1,066 1,569 1,029 
2024 Term Loan Facility(5)
— — 270 270 
2026 Term Loan Facility(5)
468 468 625 625 
_______________________
(1)The carrying amount of cash and cash equivalents approximates fair value due to the short maturity of those instruments.
(2)The carrying amount approximates fair value as the interest rate is reset frequently based on current market rates as well as the short maturity of those instruments.
(3)The carrying amount approximates fair value as the instruments are marked-to-market and held at fair value on the Consolidated Balance Sheets.
(4)The fair value of the Note is obtained from pricing services engaged by the Company, and the Company receives one price for each security. The fair value provided by the pricing services are estimated using pricing models, where the inputs to those models are based on observable market inputs or recent trades of similar securities. The inputs to the valuation techniques applied by the pricing services are typically benchmark yields, benchmark security prices, credit spreads, reported trades and broker-dealer quotes, all with reasonable levels of transparency.
(5)The carrying amount approximates fair value as the Term Loans were assumed at fair value and the interest rate is reset frequently based on current market rates.
Derivatives
Foreign Currency Forward Contracts
The Company periodically enters into foreign currency forward contracts with the objective of managing our exchange rate risk related to foreign currency denominated monetary assets and liabilities of our operations. These contracts generally involve the exchange of one currency for a second currency at a future date, have maturities not exceeding twelve months and are with counterparties which are major international financial institutions.
Commodity Contracts
The Company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as soybeans, soybean oil and soybean meal.
22
Table of Contents
The Company also utilizes options, futures and swaps that are designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of natural gas used in our manufacturing process.
Hedges Related to Issuances of Debt
As of September 30, 2024, the Company designated approximately $892 million of Euro Notes as a hedge of a portion of its net European investments. Accordingly, the change in the value of the debt that is attributable to foreign exchange movements is recorded in Other comprehensive income (“OCI”) as a component of foreign currency translation adjustments in the accompanying Consolidated Statements of Income and Comprehensive Income (Loss).
Cross Currency Swaps
The Company has twelve EUR/USD cross currency swaps with a notional value of $1.400 billion that mature through November 2030. The swaps all qualified as net investment hedges in order to mitigate a portion of the Company’s net European investments from foreign currency risk. As of September 30, 2024, the twelve swaps were in a liability position with an aggregate fair value of $164 million, which were classified as Other liabilities on the Consolidated Balance Sheets. Changes in fair value related to cross currency swaps are recorded in OCI.
The following table shows the notional amount of the Company’s derivative instruments outstanding as of September 30, 2024 and December 31, 2023:
(DOLLARS IN MILLIONS)September 30, 2024December 31, 2023
Foreign currency contracts(1)
$(3,478)$(1,400)
Commodity contracts(1)
10 7 
Cross currency swaps1,400 1,400 
_______________________
(1)Foreign currency contracts and commodity contracts are presented net of contracts bought and sold.
The following tables show the Company’s derivative instruments measured at fair value (Level 2 of the fair value hierarchy), as reflected on the Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023:
 September 30, 2024
(DOLLARS IN MILLIONS)Fair Value of
Derivatives
Designated as
Hedging
Instruments		Fair Value of
Derivatives Not
Designated as
Hedging
Instruments		Total Fair Value
Derivative assets(1)
Foreign currency contracts$— $57 $57 
Total derivative assets$— $57 $57 
Derivative liabilities(2)
Foreign currency contracts$— $3 $3 
Cross currency swaps164 — 164 
Total derivative liabilities$164 $3 $167 

 December 31, 2023
(DOLLARS IN MILLIONS)Fair Value of
Derivatives
Designated as
Hedging
Instruments		Fair Value of
Derivatives Not
Designated as
Hedging
Instruments		Total Fair Value
Derivative assets(1)
Foreign currency contracts$— $41 $41 
Total derivative assets$— $41 $41 
Derivative liabilities(2)
Foreign currency contracts$— $4 $4 
Cross currency swaps161 — 161 
Total derivative liabilities$161 $4 $165 
 _______________________
23
Table of Contents
(1)Derivative assets are recorded to Prepaid expenses and other current assets on the Consolidated Balance Sheets.
(2)Derivative liabilities are recorded to Other current liabilities and Other liabilities on the Consolidated Balance Sheets.
The following table shows the effect of the Company’s derivative instruments which were not designated as hedging instruments on the Consolidated Statements of Income and Comprehensive Income (Loss) for the three and nine months ended September 30, 2024 and 2023:
Amount of Gain (Loss)
Recognized in Income on
Derivative Settlements		Amount of Gain (Loss) Recognized in Income on Changes in Fair ValueLocation of Gain (Loss) Recognized in Income on Derivative
(DOLLARS IN MILLIONS)Three Months Ended September 30,Three Months Ended September 30,
2024202320242023
Foreign currency contracts(1)
$62 $(26)$80 $(40)Other expense (income), net
Total$62 $(26)$80 $(40)
Amount of Gain (Loss)
Recognized in Income on
Derivative Settlements		Amount of Gain (Loss) Recognized in Income on Changes in Fair ValueLocation of Gain (Loss) Recognized in Income on Derivative
(DOLLARS IN MILLIONS)Nine Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Foreign currency contracts(1)
$21 $(23)$16 $(29)Other expense (income), net
Commodity contracts(1)— — — Cost of sales
Total$20 $(23)$16 $(29)
_______________________
(1)The foreign currency contract net gains (losses) offset any recognized gains (losses) arising from the revaluation of the related intercompany loans during the same respective periods.

The following table shows the effect of the Company’s derivative and non-derivative instruments designated as cash flow and net investment hedging instruments, net of tax, on the Consolidated Statements of Income and Comprehensive Income (Loss) for the three and nine months ended September 30, 2024 and 2023:

 Amount of Gain (Loss)
Recognized in OCI on
Derivative and Non-Derivative (Effective
Portion)		Location of Gain (Loss)
Reclassified from Accumulated Other Comprehensive Income (“AOCI”) into Income (Effective Portion)		Amount of Gain (Loss)
Reclassified from
AOCI into
Income (Effective
Portion)
 Three Months Ended September 30,Three Months Ended September 30,
(DOLLARS IN MILLIONS)2024202320242023
Derivatives in Cash Flow Hedging Relationships:
Commodity contracts$1 $— Cost of sales$1 $— 
Derivatives in Net Investment Hedging Relationships:
Cross currency swaps(38)22 N/A— — 
Non-Derivatives in Net Investment Hedging Relationships:
2024 Euro Notes— 15 N/A— — 
2026 Euro Notes(28)25 N/A— — 
Total$(65)$62 $1 $— 
24
Table of Contents
 Amount of Gain (Loss)
Recognized in OCI on
Derivative and Non-Derivative (Effective
Portion)		Location of Gain (Loss)
Reclassified from AOCI into Income (Effective Portion)		Amount of Gain (Loss)
Reclassified from
AOCI into
Income (Effective
Portion)
 Nine Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Derivatives in Cash Flow Hedging Relationships:
Foreign currency contracts$(7)$— N/A$— $— 
Commodity contracts2 — Cost of sales1 — 
Derivatives in Net Investment Hedging Relationships:
Cross currency swaps(2)(11)N/A— — 
Non-Derivatives in Net Investment Hedging Relationships:
2024 Euro Notes3 4 N/A— — 
2026 Euro Notes(8)7 N/A— — 
Total$(12)$— $1 $— 
The ineffective portion of the above noted net investment hedges was approximately $3 million and $11 million for each of the three and nine months ended September 30, 2024 and 2023 respectively, and was recorded as a reduction to Interest expense on the Consolidated Statements of Income and Comprehensive Income (Loss).
At September 30, 2024, based on current market rates, the Company does not expect any material derivative losses (net of tax), included in AOCI, to be reclassified into earnings within the next 12 months.

NOTE 16.    ACCUMULATED OTHER COMPREHENSIVE LOSS
The following tables present changes in the accumulated balances for each component of other comprehensive (loss) income, including current period other comprehensive (loss) income and reclassifications out of accumulated other comprehensive loss, for the three and nine months ended September 30, 2024 and 2023:
(DOLLARS IN MILLIONS)Foreign
Currency
Translation
Adjustments		Gains (Losses) 
on Derivatives
Qualifying as
Hedges		Pension and
Postretirement
Liability
Adjustment		Total
Accumulated other comprehensive (loss) income, net of tax, as of July 1, 2024$(2,073)$(5)$(237)$(2,315)
OCI before reclassifications555 2 (3)554 
Amounts reclassified from AOCI— (1)2 1 
Net current period other comprehensive income (loss)555 1 (1)555 
Accumulated other comprehensive (loss), net of tax, as of September 30, 2024$(1,518)$(4)$(238)$(1,760)
(DOLLARS IN MILLIONS)Foreign
Currency
Translation
Adjustments		Gains (Losses) 
on Derivatives
Qualifying as
Hedges		Pension and
Postretirement
Liability
Adjustment		Total
Accumulated other comprehensive (loss) income, net of tax, as of January 1, 2024$(1,652)$1 $(245)$(1,896)
OCI before reclassifications130 (4)1 127 
Reclassifications due to business divestitures4 — — 4 
Amounts reclassified from AOCI— (1)6 5 
Net current period other comprehensive income (loss)134 (5)7 136 
Accumulated other comprehensive (loss), net of tax, as of September 30, 2024$(1,518)$(4)$(238)$(1,760)
25
Table of Contents
(DOLLARS IN MILLIONS)Foreign
Currency
Translation
Adjustments		Gains (Losses) 
on Derivatives
Qualifying as
Hedges		Pension and
Postretirement
Liability
Adjustment		Total
Accumulated other comprehensive (loss) income, net of tax, as of July 1, 2023$(1,722)$1 $(136)$(1,857)
OCI before reclassifications(477)— (2)(479)
Reclassifications due to business divestitures1 — — 1 
Amounts reclassified from AOCI— — (1)(1)
Net current period other comprehensive income (loss)(476)— (3)(479)
Accumulated other comprehensive (loss), net of tax, as of September 30, 2023$(2,198)$1 $(139)$(2,336)
(DOLLARS IN MILLIONS)Foreign
Currency
Translation
Adjustments		Gains (Losses) 
on Derivatives
Qualifying as
Hedges		Pension and
Postretirement
Liability
Adjustment		Total
Accumulated other comprehensive (loss) income, net of tax, as of January 1, 2023$(2,066)$1 $(133)$(2,198)
OCI before reclassifications(175)— (2)(177)
Reclassifications due to business divestitures43 — (1)42 
Amounts reclassified from AOCI— — (3)(3)
Net current period other comprehensive income (loss)(132)— (6)(138)
Accumulated other comprehensive (loss) income, net of tax, as of September 30, 2023$(2,198)$1 $(139)$(2,336)
The following table provides details about pension and postretirement liability reclassifications out of Accumulated other comprehensive loss to the Consolidated Statements of Income and Comprehensive Income (Loss):
Three Months Ended September 30,Affected Line Item in the Consolidated Statements of Income and Comprehensive (Loss) Income
(DOLLARS IN MILLIONS)20242023
Gains (losses) on pension and postretirement liability adjustments
Prior service cost$1 $2 
(1)
Actuarial losses(3)— 
(1)
Tax— (1)Provision for income taxes
Total$(2)$1 Total, net of income taxes
Nine Months Ended September 30,Affected Line Item in the Consolidated Statements of Income and Comprehensive Income (Loss)
(DOLLARS IN MILLIONS)20242023
Gains (losses) on pension and postretirement liability adjustments
Prior service cost$2 $4 
(1)
Actuarial losses(8)— 
(1)
Tax— (1)Provision for income taxes
Total$(6)$3 Total, net of income taxes
 _______________________
(1)The amortization of prior service cost and actuarial loss is included in the computation of net periodic benefit cost. Refer to Note 15 of the Company’s 2023 Form 10-K for additional information regarding net periodic benefit cost.

26
Table of Contents
NOTE 17.    COMMITMENTS AND CONTINGENCIES
Guarantees and Letters of Credit
The Company has various bank guarantees, letters of credit and surety bonds which are used to support its ongoing business operations, satisfy governmental requirements associated with pending litigation in various jurisdictions and the payment of customs duties.
As of September 30, 2024, the Company had a total of approximately $219 million of bank guarantees, commercial guarantees, standby letters of credit and surety bonds with various financial institutions. Included in the above aggregate amount was a total of approximately $10 million for other assessments in Brazil for various income tax and indirect tax disputes related to fiscal years 1998-2011. There was a total of approximately $64 million outstanding under the bank guarantees, standby letters of credit and commercial guarantees as of September 30, 2024.
In order to challenge the assessments in these cases in Brazil, the Company has been required to, and has separately pledged assets, principally property, plant and equipment, to cover assessments in the amount of approximately $7 million as of September 30, 2024.
Lines of Credit
The Company has various lines of credit which are available to support its ongoing business operations. As of September 30, 2024, the Company had a total capacity of approximately $1.883 billion of lines of credit with various financial institutions, in addition to the $1.347 billion of capacity under the Revolving Credit Facility. Pursuant to these lines of credit as of September 30, 2024, there were no draw downs related to the issuances of commercial paper. See Note 13 for additional information.
Litigation
The Company assesses contingencies related to litigation and/or other matters to determine the degree of probability and range of possible loss. A loss contingency is accrued in the Company’s Consolidated Financial Statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly sensitive and requires judgments about future events. On at least a quarterly basis, the Company reviews contingencies related to litigation to determine the adequacy of accruals. The amount of ultimate loss may differ from these estimates and further events may require the Company to increase or decrease the amounts it has accrued on any matter.
Periodically, the Company assesses its insurance coverage for all known claims, where applicable, taking into account aggregate coverage by occurrence, limits of coverage, self-insured retentions and deductibles, historical claims experience and claims experience with its insurance carriers. The liabilities are recorded at management’s best estimate of the probable outcome of the lawsuits and claims, taking into consideration the facts and circumstances of the individual matters as well as past experience on similar matters. At each balance sheet date, the key issues that management assesses are whether it is probable that a loss as to asserted or unasserted claims has been incurred and if so, whether the amount of loss can be reasonably estimated. The Company records the expected liability with respect to claims in Other liabilities and expected recoveries from its insurance carriers in Other assets. The Company recognizes a receivable when it believes that realization of the insurance receivable is probable under the terms of the insurance policies and its payment experience to date.
Litigation Matters
A motion to approve a securities class action was filed in the Tel Aviv District Court, Israel, in August 2019, alleging, among other things, false and misleading statements largely in connection with IFF’s acquisition of Frutarom and improper payments made by Frutarom businesses operating principally in Russia and Ukraine to representatives of customers. The motion (“Oman”) (following an initial amendment) asserted claims under the Israeli Securities Act-1968 against IFF, its former Chairman and CEO, and its former CFO, and against Frutarom and certain former Frutarom officers and directors, as well as claims under the Israeli Companies Act-1999 against certain former Frutarom officers and directors. On July 14, 2022, the court approved the parties’ motion to mediate the dispute, which postponed all case deadlines until after the mediation. The parties held mediation meetings on September 13, 2022, November 22, 2022, March 1, 2023, November 2023, March 3, 2024 and April 1, 2024. In May 2024, the court granted the parties' joint motion proposing certain case deadlines, setting an evidentiary hearing on the motion to approve class action in February 2025.
On October 29, 2019, IFF and Frutarom filed a claim in the Tel Aviv District Court, Israel, against Ori Yehudai, the former President and CEO of Frutarom, and against certain former directors of Frutarom, challenging the bonus of US $20 million granted to Yehudai in 2018. IFF and Frutarom allege, among other things, that Yehudai was not entitled to receive the bonus because he breached his fiduciary duty by, among other things, knowing of the above-mentioned improper payments and failing to prevent them from being made. The parties agreed, pursuant to the court’s recommendation, to attempt to resolve the dispute through mediation, and a court decision is pending with regard to the order in which this claim and the class action described
27
Table of Contents
below will be heard.
On March 11, 2020, an IFF shareholder filed a motion to approve a class action in Israel against, among others, Frutarom, Yehudai, and Frutarom’s former board of directors, alleging that former minority shareholders of Frutarom were harmed as a result of the US $20 million bonus paid to Yehudai. The court held an evidentiary hearing on the motion to approve a class action in March 2024.
Since March 2023, various putative class action lawsuits have been filed against IFF, Firmenich International SA, Givaudan SA, and Symrise AG and/or certain affiliates thereof in the Quebec Superior Court, the Federal Court of Canada, Ontario Superior Court, the Supreme Court of British Columbia and, in several cases, the United States District Court for the District of New Jersey. These actions allege violations of the Canadian Competition Act and the Sherman Act, as applicable, and other related claims, and seek damages and other relief. In December 2023, the Federal Court of Canada proceeding was discontinued in its entirety. IFF may face additional civil suits, in the United States or elsewhere, relating to such alleged conduct. At this time, IFF is unable to predict the potential outcome of these lawsuits or any potential effect they may have on the Company’s results of operations, liquidity or financial condition.
Investigations
On June 3, 2020, the Israel Police’s National Fraud Investigation Unit and the Israeli Securities Authority commenced an investigation into Frutarom and certain of its former executives, based on suspected bribery of foreign officials, money laundering, and violations of the Israeli Securities Act-1968. On February 26, 2024, the Israeli authorities informed Frutarom that the authorities decided to close the criminal investigation.

On March 7, 2023, the European Commission (“EC”) and the United Kingdom Competition and Markets Authority (“CMA”) carried out unannounced inspections of certain of IFF’s facilities. On the same day, IFF was served with a grand jury subpoena by the Antitrust Division of the U.S. Department of Justice (“DOJ”). IFF understands the EC, CMA, DOJ and the Swiss Competition Commission are investigating potential anticompetitive conduct as it relates to IFF’s fragrance businesses. The Mexican Competition Commission has also announced that it is investigating potential anticompetitive conduct in the fragrance and fragrance ingredients industries. IFF has been and intends to continue cooperating with these investigations. During the first three months of 2024, IFF recognized a provision of €15.9 million (approximately $17.5 million) in connection with a settlement with the EC, which was paid during the third quarter of 2024. This settlement pertains to a charge related to the deletion of messages relevant to the investigation by a former Scent employee. This settlement does not conclude the ongoing antitrust investigation. IFF is currently unable, however, to predict or determine the duration or outcome of the investigations, or whether the outcome of the investigations will materially impact the Company’s results of operations, liquidity or financial condition.

Additionally, the Company from time to time receives complaints from customers regarding product quality, performance or other aspects of its ongoing relationships. The Company is unable to determine whether the potential settlement of customer claims, if any, will materially impact the Company's results of operations, liquidity, or financial condition.
Environmental Proceedings
The Company is reporting the following environmental matter in compliance with SEC requirements to disclose environmental proceedings where a governmental authority is a party and that involve potential monetary sanctions of $300,000 or greater. Effective March 22, 2024, the Solae, LLC Memphis site (“Solae”) signed an Administrative Order on Consent (the “Consent Order”) resolving violations and penalties pertaining to the Administrative Order and Assessment received from the City of Memphis on May 27, 2022 related to alleged wastewater discharge violations. In view of the Consent Order, Solae withdrew its previously filed appeal. Pursuant to the Consent Order, Solae is completing its capital project efforts in accordance with the agreed schedule for attaining compliance with current wastewater permit requirements. This matter is not expected to have a material adverse effect on the Company’s financial position, cash flows or results of operations.
Other Contingencies
The Company has contingencies involving third parties (such as labor, contract, technology or product-related claims or litigation) as well as government-related items in various jurisdictions in which it operates pertaining to such items as value-added taxes, other indirect taxes, customs and duties and sales and use taxes. It is possible that cash flows or results of operations, in any period, could be materially affected by the unfavorable resolution of one or more of these contingencies.
The most significant government-related contingencies exist in Brazil. With regard to the Brazilian matters, the Company believes it has valid defenses for the underlying positions under dispute; however, in order to pursue these defenses, the Company is required to, and has provided, bank guarantees and pledged assets in the aggregate amount of approximately $17 million. The Brazilian matters take an extended period of time to proceed through the judicial process and there are a limited number of rulings to date.
28
Table of Contents
Other
During the third quarter of 2024, the Company entered into a confidential agreement with one of its customers, which included a payment that is not material to the financial statements. Under this agreement, the Company will gain access to incremental revenue opportunities and a release from certain claims. This payment has been capitalized as an asset and will be amortized over the period in which the associated revenue is recognized.
The Company is subject to various legal proceedings and claims that have arisen in the ordinary course of business and have not been fully resolved. Due to the inherent subjectivity and unpredictability of outcomes of legal proceedings, the Company is unable to determine, with certainty, the probability of the outcome of these matters or the range of reasonably possible losses, if any.

29
Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
(UNLESS INDICATED OTHERWISE, DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)
The following management’s discussion and analysis should be read in conjunction with the management’s discussion and analysis of financial condition and results of operations, liquidity and capital resources included in our 2023 Annual Report on Form 10-K, filed on February 28, 2024 with the SEC (“2023 Form 10-K”).

OVERVIEW
Company Background
With the Merger with N&B in 2021 and our acquisition of Frutarom Industries Ltd. in 2018, we have expanded our global leadership positions, which now include high-value ingredients and solutions in the Food & Beverage, Home & Personal Care and Health & Wellness markets, and across key Taste, Texture, Scent, Nutrition, Enzymes, Cultures, Soy Proteins, Pharmaceutical Excipients and Probiotics categories.
We are organized into four reportable operating segments: Nourish, Health & Biosciences, Scent and Pharma Solutions.
Our Nourish segment consists of an innovative and broad portfolio of natural-based ingredients to enhance nutritional value, texture and functionality in a wide range of beverage, dairy, bakery, confectionery and culinary applications and consists of Ingredients, Flavors and Food Designs.
Our Health & Biosciences segment consists of the development and production of an advanced biotechnology-derived portfolio of enzymes, food cultures, probiotics and specialty ingredients for food and non-food applications. Among many other applications, this biotechnology-driven portfolio includes cultures for use in fermented foods such as yogurt, cheese and fermented beverages, probiotic strains, many with documented clinical health claims for use as dietary supplements and through industrial fermentation the production of enzymes and microorganisms that provide product and process performance benefits to household detergents, animal feed, ethanol production and brewing. Health & Biosciences is comprised of Health, Cultures & Food Enzymes, Home & Personal Care, Animal Nutrition and Grain Processing.
Our Scent segment creates fragrance compounds and fragrance ingredients that are integral elements in the world’s finest perfumes and best-known household and personal care products. Consumer insights science and creativity are at the heart of our Scent business, and, along with our unique portfolio of natural and synthetic ingredients, global footprint, innovative technologies and know-how, and customer intimacy, we believe these make us a market leader in scent products. The Scent segment is comprised of Fragrance Compounds and Fragrance Ingredients. We completed the divestiture of our Cosmetic Ingredients business on April 2, 2024.
Our Pharma Solutions segment produces, among other things, a vast portfolio of cellulosics and seaweed-based pharmaceutical excipients, used to improve the functionality and delivery of active pharmaceutical ingredients, including controlled or modified drug release formulations, and enabling the development of more effective pharmaceutical finished dosage formulations. Our excipients are used in prescription and over-the-counter pharmaceuticals and dietary supplements. Our Pharma Solutions products also serve a variety of other specialty and industrial end-uses including coatings, inks, electronics, agriculture and consumer products. On March 19, 2024, we announced the sale process and entered into an agreement to sell the Pharma Solutions business disposal group, that is primarily made up of most businesses within the Company's existing Pharma Solutions reportable segment as well as certain adjacent businesses. During October 2024, the Company entered into an agreement to sell its nitrocellulose business, which is within the Company's existing Pharma Solutions reportable operating segment. See Note 3 for additional information.
Financial Measures — Currency Neutral
Changes in our financial results include the impact of changes in foreign currency exchange rates. We provide currency neutral calculations in this report to remove the impact of these items. We calculate currency neutral numbers by translating current year invoiced sale amounts at the exchange rates used for the corresponding prior year period. We use currency neutral results in our analysis of subsidiary and/or segment performance. We also use currency neutral numbers when analyzing our performance against our competitors.
30
Table of Contents
Impact related to the Israel-Hamas War
We maintain operations in Israel and, additionally, export products to customers in Israel from operations outside the region. We will continue to evaluate the current events and any potential impacts related to this matter, but we do not expect there to be a material impact to our Consolidated Financial Statements.
For each of the three and nine months ended September 30, 2024 and 2023, total sales to Israeli customers were less than 1% of total sales.
Impact related to the Russia-Ukraine War
We maintain operations in both Russia and Ukraine and, additionally, export products to customers in Russia and Ukraine from operations outside the region. In response to the events in Ukraine, we have limited the production and supply of ingredients in and to Russia to only those that meet the essential needs of people, including food, hygiene and medicine.
For each of the three and nine months ended September 30, 2024 and 2023, sales to Russian customers were approximately 1% of total sales.
For each of the three and nine months ended September 30, 2024 and 2023, sales to Ukrainian customers were less than 1% of total sales.
We have a reserve of approximately $2 million related to expected credit losses on receivables from customers located in Russia and Ukraine. For additional information, refer to Note 1 and Part I, Item 1A, “Risk Factors,” of our 2023 Form 10-K.
Financial Performance Overview
Sales
Sales in the third quarter of 2024 increased $105 million, or 4% on a reported basis, to $2.925 billion compared to $2.820 billion in the 2023 period. On a currency neutral basis, sales in the third quarter of 2024 increased 7% compared to the 2023 period. Exchange rate variations had an unfavorable impact on net sales for the third quarter of 2024 of 3%. The effect of exchange rates can vary by business and region, depending upon the mix of sales priced in U.S. dollars as compared to other currencies. The increase in currency neutral sales was primarily driven by volume increases across various businesses, offset by divestiture impacts of approximately $23 million from the sale of the Cosmetic Ingredients business.
Gross profit in the third quarter of 2024 increased $128 million, or 14%, to $1.052 billion (36.0% of sales) compared to $924 million (32.8% of sales) in the 2023 period. The increase in gross profit was primarily driven by volume increases and favorable net pricing, offset in part by unfavorable exchange rate variations and divestiture impacts from the sale of the Cosmetic Ingredients business.
31
Table of Contents
RESULTS OF OPERATIONS
Three Months EndedNine Months Ended
 September 30, September 30, 
(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)20242023Change20242023Change
Net sales$2,925 $2,820 4 %$8,713 $8,776 (1)%
Cost of Sales1,873 1,896 (1)%5,569 5,955 (6)%
Gross profit1,052 924 14 %3,144 2,821 11 %
Research and development (R&D) expenses162 157 3 %501 479 5 %
Selling and administrative (S&A) expenses495 444 11 %1,478 1,343 10 %
Amortization of acquisition-related intangibles146 170 (14)%467 513 (9)%
Impairment of goodwill— — NMF64 — NMF
Restructuring and other charges1 2 (50)%6 61 (90)%
(Gains) losses on sale of assets(1)1 (200)%(11)(1)NMF
Operating profit249 150 66 %639 426 50 %
Interest expense74 90 (18)%236 291 (19)%
(Gains) losses on business disposals20 10 100 %(348)29 NMF
Loss on assets classified as held for sale32 — NMF314 — NMF
Other expense (income), net28 (9)NMF44 (17)NMF
Income before income taxes95 59 61 %393 123 220 %
Provision for income taxes35 32 9 %100 77 30 %
Net income$60 $27 122 %$293 $46 NMF
Net income attributable to non-controlling interests1 2 (50)%4 3 33 %
Net income attributable to IFF shareholders$59 $25 136 %$289 $43 NMF
Net income per share - diluted$0.23 $0.10 130 %$1.13 $0.16 NMF
Gross margin36.0 %32.8 %NMF36.1 %32.1 %NMF
R&D as a percentage of sales5.5 %5.6 %(10) bps5.8 %5.5 %30 bps
S&A as a percentage of sales16.9 %15.7 %120 bps17.0 %15.3 %170 bps
Operating margin8.5 %5.3 %NMF7.3 %4.9 %240 bps
Effective tax rate36.8 %54.2 %NMF25.4 %62.6 %NMF
Segment net sales
Nourish$1,486 $1,449 3 %$4,460 $4,666 (4)%
Health & Biosciences570 518 10 %1,659 1,553 7 %
Scent613 615 — %1,861 1,815 3 %
Pharma Solutions256 238 8 %733 742 (1)%
Consolidated$2,925 $2,820 $8,713 $8,776 
_______________________ 
NMF: Not meaningful
Cost of goods sold includes the cost of materials and manufacturing expenses. R&D expenses include expenses related to the development of new and improved products and technical product support. S&A expenses include expenses necessary to support our commercial activities and administrative expenses supporting our overall operating activities including compliance with governmental regulations.

32
Table of Contents
THIRD QUARTER 2024 IN COMPARISON TO THIRD QUARTER 2023
Sales Performance by Segment
% Change in Sales - Third Quarter 2024 vs. Third Quarter 2023
Reported
Currency Neutral(1)
Nourish3 %6 %
Health & Biosciences10 %12 %
Scent0 %5 %
Pharma Solutions8 %8 %
Total4 %7 %
_______________________ 
(1)Currency neutral sales is calculated by translating current year invoiced sale amounts at the exchange rates for the corresponding prior year period.
Nourish
Nourish sales in 2024 increased $37 million, or 3% on a reported basis, to $1.486 billion compared to $1.449 billion in the prior year period. On a currency neutral basis, Nourish sales increased 6% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. Performance in the Nourish operating segment was driven by volume increases across various business units.
Health & Biosciences
Health & Biosciences sales in 2024 increased $52 million, or 10% on a reported basis, to $570 million compared to $518 million in the prior year period. On a currency neutral basis, Health & Biosciences sales increased 12% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. Performance in the Health & Biosciences operating segment was driven by volume increases across all business units.
Scent
Scent sales in 2024 remained flat at $613 million compared to $615 million in the prior year period. On a currency neutral basis, Scent sales increased 5% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. Performance in the Scent operating segment was driven by price increases in the fragrance compounds business unit and volume increases in the fragrance compounds and fragrance ingredients business units, offset in part by the divestitures of the Cosmetic Ingredients business with an impact of approximately $23 million.
Pharma Solutions
Pharma Solutions sales in 2024 increased $18 million, or 8% on a reported basis, to $256 million compared to $238 million in the prior year period. On a currency neutral basis, Pharma Solutions sales increased by 8% as exchange rate variations were flat in 2024 compared to the prior year. Performance in the Pharma Solutions operating segment was driven by volume increases across Pharma and Industrial end markets.
Cost of Goods Sold
Cost of goods sold decreased $23 million to $1.873 billion (64.0% of sales) in the third quarter of 2024 compared to $1.896 billion (67.2% of sales) in the third quarter of 2023. The decrease in cost of goods sold was primarily driven by lower raw material costs and manufacturing expenses, lower unfavorable manufacturing absorption compared to the prior year period, offset in part by volume increases in sales.
Research and Development (R&D) Expenses
R&D expenses increased $5 million to $162 million (5.5% of sales) in the third quarter of 2024 compared to $157 million (5.6% of sales) in the third quarter of 2023. The increase in R&D expenses was primarily driven by an increase in incentive compensation expense.
Selling and Administrative (S&A) Expenses
S&A expenses increased $51 million to $495 million (16.9% of sales) in the third quarter of 2024 compared to $444 million (15.7% of sales) in the third quarter of 2023. The increase in S&A expenses was primarily driven by increased incentive compensation expense and divestiture related costs incurred in preparation for the sale of the Pharma Solutions disposal group.
33
Table of Contents
Amortization of Acquisition-Related Intangibles
Amortization expenses decreased to $146 million in the third quarter of 2024 compared to $170 million in the third quarter of 2023. The decrease in amortization expense was primarily driven by the reduction in intangible assets as a result of the change in business portfolio mix due to divestitures and intangible assets of the Pharma Solutions disposal group being classified as “held for sale”, and therefore no longer recognizing amortization expense on those intangible assets. See Note 3 for additional information.
Restructuring and Other Charges
Restructuring and other charges was $1 million in the third quarter of 2024 compared to $2 million in the third quarter of 2023. The decrease was driven by lower severance costs incurred compared to the prior year period. See Note 4 for additional information.
Interest Expense
Interest expense decreased to $74 million in the third quarter of 2024 compared to $90 million in the third quarter of 2023. The decrease in interest expense was due to lower debt outstanding. See Note 13 for additional information.
Losses on Business Disposals
Losses on business disposals increased to $20 million in the third quarter of 2024 compared to $10 million in the third quarter of 2023. The increase was primarily driven by the loss recognized on the F&E UK divestiture. See Note 3 for additional information.
Loss on Assets Classified as Held for Sale
Loss on assets classified as held for sale was $32 million in the third quarter of 2024. This is related to assets classified as held for sale for the Pharma Solutions disposal group and the portion of the Savory Solutions business in Turkey. See Note 3 for additional information.
Other Expense (Income), Net
Other expense (income), net, was $28 million in the third quarter of 2024 compared to $(9) million in the third quarter of 2023. The increase of $37 million was primarily due to higher foreign exchange losses in 2024. See Note 8 for additional information.
Income Taxes
The effective tax rate for the three months ended September 30, 2024 was 36.8% compared to 54.2% for the three months ended September 30, 2023. The quarter-over-quarter decrease was primarily driven by an increase in pre-tax income, changes in the mix of earnings and in tax charges on business divestitures.
Segment Adjusted Operating EBITDA Results
The Company uses Segment Adjusted Operating EBITDA for internal reporting and performance measurement purposes. Segment Adjusted Operating EBITDA is defined as Income Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges and certain items that are not related to recurring operations. Our determination of reportable segments was made on the basis of our strategic priorities within each segment and corresponds to the manner in which our Chief Operating Decision Maker reviews and evaluates operating performance to make decisions about resources to be allocated to the segment. In addition to our strategic priorities, segment reporting is also based on differences in the products and services we provide.
34
Table of Contents
 Three Months Ended September 30,
(DOLLARS IN MILLIONS)20242023
Segment Adjusted Operating EBITDA:
Nourish$206 $178 
Health & Biosciences173 150 
Scent127 131 
Pharma Solutions62 47 
Total568 506 
Depreciation & Amortization(248)(292)
Interest Expense(74)(90)
Other (Expense) Income, net(28)9 
Restructuring and Other Charges(1)(2)
Gains (Losses) on Business Disposals(20)(10)
Loss on Assets Classified as Held for Sale(32)— 
Acquisition, Divestiture and Integration Costs(55)(42)
Strategic Initiatives Costs(6)(6)
Regulatory Costs(10)(13)
Other1 (1)
Income Before Taxes$95 $59 
Segment Adjusted Operating EBITDA margin:
Nourish13.9 %12.3 %
Health & Biosciences30.4 %29.0 %
Scent20.7 %21.3 %
Pharma Solutions24.2 %19.7 %
Consolidated19.4 %17.9 %
Nourish Segment Adjusted Operating EBITDA
Nourish Segment Adjusted Operating EBITDA increased $28 million, or 16% on a reported basis, to $206 million in the third quarter of 2024 (13.9% of segment sales) from $178 million (12.3% of segment sales) in the comparable 2023 period. On a currency neutral basis, Nourish Segment Adjusted Operating EBITDA increased 25% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. In addition, the performance was primarily driven by volume increases and favorable net pricing.
Health & Biosciences Segment Adjusted Operating EBITDA
Health & Biosciences Segment Adjusted Operating EBITDA increased $23 million, or 15% on a reported basis, to $173 million in the third quarter of 2024 (30.4% of segment sales) from $150 million (29.0% of segment sales) in the comparable 2023 period. On a currency neutral basis, Health & Biosciences Segment Adjusted Operating EBITDA increased 19% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. In addition, the performance was primarily driven by volume increases and favorable net pricing.
Scent Segment Adjusted Operating EBITDA
Scent Segment Adjusted Operating EBITDA decreased $4 million, or 3% on reported basis, to $127 million in the third quarter of 2024 (20.7% of segment sales) from $131 million (21.3% of segment sales) in the comparable 2023 period. On a currency neutral basis, Scent Segment Adjusted Operating EBITDA increased 13% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. In addition, the performance was primarily driven by volume increases and favorable net pricing, offset in part by the impact of the divestiture of the Cosmetic Ingredients business.
35
Table of Contents
Pharma Solutions Segment Adjusted Operating EBITDA
Pharma Solutions Segment Adjusted Operating EBITDA increased $15 million, or 32% on a reported basis, to $62 million in the third quarter of 2024 (24.2% of segment sales) from $47 million (19.7% of segment sales) in the comparable 2023 period. On a currency neutral basis, Pharma Solutions Segment Adjusted Operating EBITDA increased 31% in 2024 compared to the prior year period as exchange rate variations were flat. The increase was primarily driven by volume increases, improved utilization and productivity gains.

FIRST NINE MONTHS 2024 IN COMPARISON TO FIRST NINE MONTHS 2023
Sales
Sales for the first nine months of 2024 decreased $63 million, or 1% on a reported basis, to $8.713 billion compared to $8.776 billion in the 2023 period. On a currency neutral basis, sales for the first nine months of 2024 increased 3% compared to the 2023 period, as exchange rate variations had an unfavorable impact on net sales in the first nine months of 2024. The effect of exchange rates can vary by business and region, depending upon the mix of sales priced in U.S. dollars as compared to other currencies. In addition, the decrease in sales was primarily driven by the divestiture impacts of the portion of the Savory Solutions business, Flavors Specialty Ingredients (“FSI”) business, and Cosmetic Ingredients business (“change in business portfolio mix due to divestitures”), which was approximately $314 million, offset in part by volume increases across various business lines.
Sales Performance by Segment 
% Change in Sales - First Nine Months 2024 vs. First Nine Months 2023
Reported
Currency Neutral(1)
Nourish-4 %-1 %
Health & Biosciences7 %9 %
Scent3 %8 %
Pharma Solutions-1 %-1 %
Total-1 %3 %
_______________________ 
(1)Currency neutral sales is calculated by translating current year invoiced sale amounts at the exchange rates for the corresponding prior year period.
Nourish
Nourish sales in 2024 decreased $206 million, or 4% on a reported basis, to $4.460 billion compared to $4.666 billion in the prior year period. On a currency neutral basis, Nourish sales decreased 1% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. In addition, performance in the Nourish operating segment was driven by the divestiture of the portion of the Savory Solutions business with an impact of approximately $222 million and price decreases, offset in part by volume increases across all business units.
Health & Biosciences
Health & Biosciences sales in 2024 increased $106 million, or 7% on a reported basis, to $1.659 billion compared to $1.553 billion in the prior year period. On a currency neutral basis, Health & Biosciences sales increased 9% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. Performance in the Health & Biosciences operating segment was driven by volume increases across all business units and price increases across Cultures & Food Enzymes and Grain Processing business units.
Scent
Scent sales in 2024 increased $46 million, or 3% on a reported basis, to $1.861 billion compared to $1.815 billion in the prior year period. On a currency neutral basis, Scent sales increased 8% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. Performance in the Scent operating segment was driven by price increases in the Fragrance Compounds business unit and volume increases across all business units, offset in part by the divestiture of the FSI business and Cosmetic Ingredients business, with an impact of approximately $92 million.
36
Table of Contents
Pharma Solutions
Pharma Solutions sales in 2024 decreased $9 million, or 1% on a reported basis, to $733 million compared to $742 million in the prior year period. On a currency neutral basis, Pharma Solutions sales also decreased 1% in 2024 compared to the prior year period as exchange rate variations had no impact. Performance in the Pharma Solutions operating segment was driven by price decreases offset in part by volume growth in industrial markets.
Cost of Goods Sold
Cost of goods sold decreased $386 million to $5.569 billion (63.9% of sales) in the first nine months of 2024 compared to $5.955 billion (67.9% of sales) in the 2023 period. The decrease in cost of goods sold was primarily driven by the change in business portfolio mix due to divestitures which was approximately $206 million, lower raw material costs and manufacturing expenses, lower unfavorable manufacturing absorption compared to the prior year period, positive net pricing and productivity compared to the prior year period, offset in part by volume increases.
Research and Development (R&D) Expenses
R&D expenses increased $22 million to $501 million (5.8% of sales) in the first nine months of 2024 compared to $479 million (5.5% of sales) in the 2023 period. The increase in R&D expenses was primarily driven by an increase in incentive compensation expense, offset in part by the net impact of the change in business portfolio mix due to divestitures.
Selling and Administrative (S&A) Expenses
S&A expenses increased $135 million to $1.478 billion (17.0% of sales) in the first nine months of 2024 compared to $1,343 million (15.3% of sales) in the 2023 period. The increase in S&A expenses was primarily driven by an increase in incentive compensation expense, professional fees, legal fees and provisions incurred for the ongoing investigations of the fragrance businesses, and divestiture related costs incurred in preparation for the sale of the Pharma Solutions disposal group, offset in part by the change in business portfolio mix due to divestitures.
Amortization of Acquisition-Related Intangibles
Amortization expenses decreased to $467 million in the first nine months of 2024 compared to $513 million in the 2023 period. The decrease in amortization expense was primarily driven by the reduction in intangible assets as a result of the change in business portfolio mix due to divestitures and intangible assets of the Pharma Solutions disposal group being classified as “held for sale”, and therefore no longer recognizing amortization expense on those intangible assets. See Note 3 for additional information.
Impairment of Goodwill
The impairment of goodwill was $64 million in the first nine months of 2024. See Note 3 for additional information.
Restructuring and Other Charges
Restructuring and other charges decreased to $6 million in the first nine months of 2024 compared to $61 million in the 2023 period. The decrease was driven by higher severance costs incurred as part of the 2023 Restructuring Program, net of reversals of prior severance cost accruals, in the first nine months of 2023. See Note 4 for additional information.
Interest Expense
Interest expense decreased to $236 million in the first nine months of 2024 compared to $291 million in the 2023 period. The decrease in interest expense was due to lower debt outstanding (see Note 13 for additional information).
(Gains) Losses on Business Disposals
(Gains) losses on business disposals increased to $(348) million in the first nine months of 2024 compared to $29 million in the 2023 period. The net gain on business disposals in 2024 primarily relates to the gain recognized on the sale of the Cosmetic Ingredients business, offset in part by the loss recognized on the sale of the F&E UK business. The loss in the 2023 period relates to the sale of the FSI business, the sale of a portion of the Savory Solutions business, and liquidation of a business in Russia for the sale of the portion of the Savory Solutions business. See Note 3 for additional information.
Loss on Assets Classified as Held for Sale
Loss on assets classified as held for sale was $314 million in the first nine months of 2024. This related to assets classified as held for sale for the Pharma Solutions disposal group and the portion of the Savory Solutions business in Turkey. See Note 3 for additional information.
37
Table of Contents
Other Expense (Income), Net
Other expense (income), net, was $44 million in the first nine months of 2024 compared to $(17) million in the 2023 period. The change of $61 million was primarily due to increased foreign exchange losses, in addition to the gain recognized on the China facility relocation in the 2023 period. See Note 8 for additional information.
Income Taxes
The effective tax rate for the nine months ended September 30, 2024 was 25.4% compared to 62.6% for the nine months ended September 30, 2023. The year-over-year decrease was primarily driven by an increase in pre-tax income, changes in the mix of earnings and in tax charges on business divestitures.
Segment Adjusted Operating EBITDA Results
The Company uses Segment Adjusted Operating EBITDA for internal reporting and performance measurement purposes. Segment Adjusted Operating EBITDA is defined as Income Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges and certain items that are not related to recurring operations. Our determination of reportable segments was made on the basis of our strategic priorities within each segment and corresponds to the manner in which our Chief Operating Decision Maker reviews and evaluates operating performance to make decisions about resources to be allocated to the segment. In addition to our strategic priorities, segment reporting is also based on differences in the products and services we provide.
 Nine Months Ended September 30,
(DOLLARS IN MILLIONS)20242023
Segment Adjusted Operating EBITDA:
Nourish$654 $567 
Health & Biosciences497 426 
Scent421 353 
Pharma Solutions162 173 
Total1,734 1,519 
Depreciation & Amortization(772)(855)
Interest Expense(236)(291)
Other (Expense) Income, net(44)17 
Restructuring and Other Charges(6)(61)
Impairment of Goodwill(64)— 
Gains (Losses) on Business Disposals348 (29)
Loss on Assets Classified as Held for Sale(314)— 
Acquisition, Divestiture and Integration Costs(172)(118)
Strategic Initiatives Costs(22)(28)
Regulatory Costs(64)(32)
Other5 1 
Income Before Taxes$393 $123 
Segment Adjusted Operating EBITDA margin:
Nourish14.7 %12.2 %
Health & Biosciences30.0 %27.4 %
Scent22.6 %19.4 %
Pharma Solutions22.1 %23.3 %
Consolidated19.9 %17.3 %
38
Table of Contents
Nourish Segment Adjusted Operating EBITDA
Nourish Segment Adjusted Operating EBITDA increased $87 million, or 15% on a reported basis, to $654 million in the first nine months of 2024 (14.7% of segment sales) from $567 million (12.2% of segment sales) in the comparable 2023 period. On a currency neutral basis, Nourish Segment Adjusted Operating EBITDA increased 29% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. The performance was primarily driven by favorable net pricing, productivity gains and volume increases, offset in part by the impact of the divestiture of the portion of the Savory Solutions business.
Health & Biosciences Segment Adjusted Operating EBITDA
Health & Biosciences Segment Adjusted Operating EBITDA increased $71 million, or 17% on a reported basis, to $497 million in the first nine months of 2024 (30.0% of segment sales) from $426 million (27.4% of segment sales) in the comparable 2023 period. On a currency neutral basis, Health & Biosciences Segment Adjusted Operating EBITDA increased 19% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. The performance was primarily driven by volume increases and favorable net pricing.
Scent Segment Adjusted Operating EBITDA
Scent Segment Adjusted Operating EBITDA increased $68 million, or 19% on a reported basis, to $421 million in the first nine months of 2024 (22.6% of segment sales) from $353 million (19.4% of segment sales) in the comparable 2023 period. On a currency neutral basis, Scent Segment Adjusted Operating EBITDA increased 41% in 2024 compared to the prior year period as exchange rate variations had an unfavorable impact. The performance was primarily driven by favorable net pricing, productivity gains and volume increases, offset in part by the impact of the divestiture of the FSI business and Cosmetic Ingredients business.
Pharma Solutions Segment Adjusted Operating EBITDA
Pharma Solutions Segment Adjusted Operating EBITDA decreased $11 million, or 6% on a reported basis, to $162 million in the first nine months of 2024 (22.1% of segment sales) from $173 million (23.3% of segment sales) in the comparable 2023 period. On a currency neutral basis, Pharma Solutions Segment Adjusted Operating EBITDA decreased 6% in 2024 compared to the prior year period as exchange rate variations remained flat. The decreased performance was primarily driven by higher costs including favorable one-off items in the 2023 period which did not recur in the 2024 period.

Liquidity
Cash and Cash Equivalents
We had cash and cash equivalents of $569 million, inclusive of $2 million currently in Assets held for sale on the Consolidated Balance Sheets, at September 30, 2024 compared to $729 million, inclusive of $26 million in Assets held for sale on the Consolidated Balance Sheets, at December 31, 2023 and of this balance, a portion was held outside the United States. Cash balances held in foreign jurisdictions are, in most circumstances, available to be repatriated to the United States.
Effective utilization of the cash generated by our international operations is a critical component of our strategy. We regularly repatriate cash from our non-U.S. subsidiaries to fund financial obligations in the U.S. As we repatriate these funds to the U.S., there will be required income taxes payable in certain U.S. states and applicable foreign withholding taxes during the period when such repatriation occurs. Accordingly, as of September 30, 2024, we had a deferred tax liability of approximately $167 million for the effect of repatriating the funds to the U.S., attributable to various non-U.S. subsidiaries. There is no deferred tax liability associated with non-U.S. subsidiaries where we intend to indefinitely reinvest the earnings to fund local operations and/or capital projects.
Cash Flows Provided By Operating Activities
Cash flows provided by operating activities for the nine months ended September 30, 2024 was $702 million, or 8.1% of sales, compared to $795 million, or 9.1% of sales, for the nine months ended September 30, 2023. The decrease in cash flows from operating activities during 2024 was primarily driven by an increase in working capital, largely related to accounts receivable and inventories including amounts held for sale, offset in part by accounts payable and higher cash earnings, excluding the impact of non-cash adjustments.
39
Table of Contents
Cash Flows Provided By Investing Activities
Cash flows provided by investing activities for the nine months ended September 30, 2024 was $586 million compared to $638 million in the prior year period. The decrease in cash flows provided by investing activities was primarily driven by lower net proceeds received from business divestitures compared to the prior year period, offset in part by decreased additions to property, plant and equipment.
We have evaluated and re-prioritized our capital projects and expect that capital spending in 2024 will be approximately 4.8% of sales (net of potential grants and other reimbursements from government authorities), up from 4.4% in 2023.
Cash Flows Used In Financing Activities
Cash flows used in financing activities for the nine months ended September 30, 2024 was $1,444 million compared to $1,293 million in the prior year period. The increase in cash flows used in financing activities was primarily driven by higher repayments of long-term debt, offset in part by lower dividends and higher repayments in the prior year period of commercial paper and amounts under the Revolving Credit Facility.
We paid dividends totaling $411 million in the 2024 period. We declared a cash dividend per share of $0.40 in the third quarter of 2024 that was paid on October 9, 2024 to all shareholders of record as of September 20, 2024.
Our capital allocation strategy seeks to maintain our investment grade rating while investing in the business and continuing to pay dividends and repaying debt. The Company does not have any rating downgrade triggers that would accelerate the maturity dates of its senior unsecured debt. However, any downgrade in our credit rating may, depending on the extent of such downgrade, negatively impact our ability to raise additional debt capital, our liquidity and capital position, and may increase our cost of borrowing for new capital raises. In addition, our existing Revolving Credit Facility and Term Loans have pricing grids that are based on credit rating, such that our cost of borrowing may increase as our credit rating decreases. We make capital investments in our businesses to support our operational needs and strategic long-term plans. We are committed to maintaining our history of paying a dividend to investors which is determined by our Board of Directors at its discretion based on various factors.
Capital Resources
Operating cash flow provides the primary source of funds for capital investment needs, dividends paid to shareholders and debt service repayments. We anticipate that cash flows from operations, cash proceeds generated from planned business divestitures and availability under our existing credit facilities will be sufficient to meet our investing and financing needs, including our debt service requirements for the foreseeable future. We regularly assess our capital structure, including both current and long-term debt instruments, as compared to our cash generation and investment needs in order to provide ample flexibility and to optimize our leverage ratios. See Note 13 for additional information.
Term Loans and Revolving Credit Facility
Our credit agreements contain various covenants, limitations and events of default customary for similar facilities for similarly rated borrowers, including the requirement for us to maintain, at the end of each fiscal quarter, a ratio of net debt for borrowed money to credit adjusted EBITDA in respect of the previous 12-month period.
Our Term Loans and Revolving Credit Facility bear interest at a base rate or a rate equal to Term SOFR plus an adjustment of 0.10% per annum or, in the case of euro-denominated loans, the Euro interbank offered rate, plus, in each case, an applicable margin based on our public debt rating. Loans may be prepaid without premium or penalty, subject to customary breakage costs.
40
Table of Contents
Based on the amendments entered into on September 19, 2023 for our Term Loans and Revolving Credit Facility, we were provided with a financial covenant relief period through December 31, 2025, or such earlier date on which we elect to terminate such period, by providing that during the financial covenant relief period, our net debt to credit adjusted EBITDA ratio shall not exceed as of the end of the fiscal quarter for the period of the four fiscal quarters then ended: (i) 5.25x for any fiscal quarter ending on or before March 31, 2024, (ii) 4.75x for the fiscal quarter ending June 30, 2024, (iii) 4.50x for the fiscal quarter ending September 30, 2024, (iv) 4.25x for any subsequent fiscal quarter ending on or before March 31, 2025, (v) 4.00x for any subsequent fiscal quarter ending on or before September 30, 2025 and (vi) 3.75x for the fiscal quarter ending December 31, 2025. During the financial covenant relief period, the amendments prohibit us from (i) effecting share repurchases, (ii) declaring and paying dividends in cash on common stock in excess of $0.81 per share per fiscal quarter (for an aggregate amount of $3.24 per fiscal year) and (iii) creating liens to secure debt in excess of the greater of $300 million and 3.65% of Consolidated Net Tangible Assets (as defined in the amendments to our Term Loans and Revolving Credit Facility), in each case subject to certain exceptions set forth therein.
As of September 30, 2024, we had no outstanding borrowings under our $2.000 billion Revolving Credit Facility. The amount that we are able to draw down under the Revolving Credit Facility is limited by financial covenants as described in more detail below. As of September 30, 2024, our available capacity was $1.347 billion under the Revolving Credit Facility.
Refer to Note 13 of this Form 10-Q and Part IV, Item 15, “Exhibits and Financial Statement Schedules,” Note 9 of our 2023 Form 10-K for additional information.
Debt Covenants
At September 30, 2024, we were in compliance with all financial and other covenants, including the net debt to credit adjusted EBITDA(1) ratio. At September 30, 2024, our net debt to credit adjusted EBITDA(1) ratio was 3.89 to 1.0 as defined by the credit facility agreements, which is below the relevant level provided by our financial covenants of existing outstanding debt. The most comparable GAAP measure is the total debt to net loss ratio, which was (3.93) to 1.0 at September 30, 2024.
_______________________ 
(1)Credit adjusted EBITDA and net debt, which are non-GAAP measures used for these covenants, are calculated in accordance with the definition in the debt agreements. In this context, these measures are used solely to provide information on the extent to which we are in compliance with debt covenants and may not be comparable to credit adjusted EBITDA and net debt used by other companies. Reconciliations of credit adjusted EBITDA to net loss and net debt to total debt are as follows:
(DOLLARS IN MILLIONS)Twelve Months Ended September 30, 2024
Net loss$(2,321)
Interest expense325 
Income taxes68 
Depreciation and amortization1,059 
Specified items(1)
3,038 
Non-cash items(2)
32 
Credit Adjusted EBITDA$2,201 
_______________________ 
(1)Specified items consisted of restructuring and other charges, impairment of goodwill, acquisition, divestiture and integration costs, strategic initiatives costs, regulatory costs and other costs that are not related to recurring operations.
(2)Non-cash items consisted of losses (gains) on sale of assets, losses (gains) on business disposals, losses on assets classified as held for sale, gain on China facility relocation, write-down of inventory related to Locust Bean Kernel and stock-based compensation.
(DOLLARS IN MILLIONS)September 30, 2024
Total debt(1)
$9,127 
Adjustments:
Cash and cash equivalents(2)
569 
Net debt$8,558 
_______________________
(1)Total debt used for the calculation of net debt consisted of short-term debt, long-term debt, short-term finance lease obligations and long-term finance lease obligations.
(2)Cash and cash equivalents included approximately $2 million currently in Assets held for sale on the Consolidated Balance Sheets.
Senior Notes
41
Table of Contents
As of September 30, 2024, we had $8.544 billion aggregate principal amount outstanding in senior unsecured notes, with $894 million principal amount denominated in EUR and $7.650 billion principal amount denominated in USD. The notes bear effective interest rates ranging from 1.22% per year to 5.12% per year, with maturities from October 1, 2025 to December 1, 2050. See Note 13 for additional information.
Contractual Obligations
We expect to contribute a total of $5 million to our U.S. pension plans and a total of $23 million to our non-U.S. pension plans during 2024. During the nine months ended September 30, 2024, $1 million of contributions were made to the qualified U.S. pension plans, $14 million of contributions were made to the non-U.S. pension plans and $3 million of contributions were made with respect to the non-qualified U.S. pension plan. We also expect to contribute $4 million to our postretirement benefits other than pension plans during 2024. During the nine months ended September 30, 2024, $2 million of benefit payments were made to postretirement benefits other than pension plans.
As discussed in Note 17 to the Consolidated Financial Statements, at September 30, 2024, we had entered into various guarantees and had undrawn outstanding letters of credit from financial institutions. These arrangements reflect ongoing business operations, including commercial commitments, and governmental requirements associated with audits or litigation that are in process with various jurisdictions. Based on the current facts and circumstances, these arrangements are not reasonably likely to have a material impact on our consolidated financial condition, results of operations or cash flows.
Critical Accounting Policies and Use of Estimates
There have been no significant changes to our critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023, except with respect to our goodwill impairment assessment. As discussed in Note 3, the Company performed a quantitative goodwill impairment assessment of the Pharma Solutions disposal group. We estimated the fair value of the Pharma Solutions disposal group, based on the price at which the Company has agreed to sell the disposal group including the fair value of contingent consideration expected to be received in the form of earn outs. The fair value of the earn outs were based on a Monte Carlo simulation. The fair value estimation uses Level 3 unobservable inputs as categorized within the ASC Topic 820 fair value hierarchy. This method considers the terms and conditions of the earn outs as described in the relevant transaction agreements, our best estimates of forecasted EBITDA for the earn out periods as applicable, and assumptions such as risk-adjusted discount rate, EBITDA volatility, counterparty discount rate and risk-free rate. The simulation consists first in risk-adjusting the EBITDA projections using a risk-adjusted discount rate and then simulating a range of EBITDAs over the applicable period using the estimate of EBITDA volatility. The fair value of the earn outs are estimated as the present value of the potential range of payouts averaged across the range of simulated EBITDAs using the counterparty discount rate. A 10% increase or decrease in the fair value of contingent consideration would not have a material impact to the impairment charge.
During the second quarter of 2024, the Company performed quantitative goodwill impairment assessments of its Pharma Solutions reporting unit before and after classification of the disposal group as held for sale. Goodwill allocated to the Pharma Solutions reporting unit was $1.2 billion before classification of the disposal group as held for sale and $74 million after classification of the disposal group as held for sale. Neither test resulted in goodwill impairment. For the pre-classification impairment assessment, we estimated the fair value of the Pharma Solutions reporting unit based upon the fair value of the held for sale disposal group as described above and the estimated fair value of the portion of the Pharma Solutions reporting unit that was not classified as held for sale (“remaining Pharma Solutions reporting unit”). For both the pre- and post-classification impairment assessments, we estimated the fair value of the remaining Pharma Solutions reporting unit based upon the estimated sale proceeds we would expect to receive in a transaction between willing market participants.
New Accounting Standards
Refer to Note 1 to the Consolidated Financial Statements for a discussion of recent accounting pronouncements.
Non-GAAP Financial Measures
We use non-GAAP financial measures in this Form 10-Q, including: (i) currency neutral metrics and (ii) adjusted operating EBITDA and adjusted operating EBITDA margin. We also provide the non-GAAP measure net debt solely for the purpose of providing information on the extent to which the Company is in compliance with debt covenants contained in its debt agreements. Our non-GAAP financial measures are defined below.
42
Table of Contents
These non-GAAP financial measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculation of such metrics.
Adjusted operating EBITDA and adjusted operating EBITDA margin exclude depreciation and amortization expense, interest expense, other (expense) income, net, restructuring and other charges and certain items unrelated to recurring operations such as impairment of goodwill, gains (losses) on business disposals, loss on assets classified as held for sale, acquisition, divestiture and integration related costs, strategic initiatives costs, regulatory costs and other costs that are not related to recurring operations.
Net debt to credit adjusted EBITDA is the leverage ratio used in our credit agreement and defined as net debt divided by credit adjusted EBITDA. However, as credit adjusted EBITDA for these purposes was calculated in accordance with the provisions of the credit agreement, it may differ from the calculation used for adjusted operating EBITDA.

Cautionary Statement Under the Private Securities Litigation Reform Act of 1995
Statements in this Form 10-Q, which are not historical facts or information, are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management’s current assumptions, estimates and expectations and include statements concerning (i) expected cash flow and availability of capital resources to fund our operations and meet our debt service requirements; (ii) our ability to execute on our strategic and financial transformation, including the progress and success of our portfolio optimization strategy (including the sale process for our Pharma Solutions disposal group), through non-core business divestitures and acquisitions, and expectations regarding the implementation of our refreshed growth-focused strategy and expectations around our business divestitures; (iii) our ability to continue to generate value for, and return cash to, our shareholders; (iv) expectations of the impact of inflationary pressures and the pricing actions to offset exposure to such impacts; (v) the impact of high input costs, including commodities, raw materials, transportation and energy; (vi) the expected impact of global supply chain challenges; (vii) our ability to enhance our innovation efforts, drive cost efficiencies and execute on specific consumer trends and demands; (viii) the growth potential of the markets in which we operate, including the emerging markets; (ix) expectations regarding sales and profit for the fiscal year 2024, including the impact of foreign exchange, pricing actions, raw materials, energy, and sourcing, logistics and manufacturing costs; (x) the impact of global economic uncertainty and recessionary pressures on demand for consumer products; (xi) the success of our integration efforts, following the N&B Transaction, and ability to deliver on our synergy commitments as well as future opportunities for the combined company; (xii) our strategic investments in capacity and increasing inventory to drive improved profitability; (xiii) our ability to drive cost discipline measures and the ability to recover margin to pre-inflation levels; (xiv) expected capital expenditures in 2024; and (xv) the expected costs and benefits of our ongoing optimization of our manufacturing operations, including the expected number of closings. These forward-looking statements should be evaluated with consideration given to the many risks and uncertainties inherent in our business that could cause actual results and events to differ materially from those in the forward-looking statements. Certain of such forward-looking information may be identified by such terms as “expect”, “anticipate”, “believe”, “intend”, “outlook”, “may”, “estimate”, “should”, “predict” and similar terms or variations thereof. Such forward-looking statements are based on a series of expectations, assumptions, estimates and projections about the Company, are not guarantees of future results or performance, and involve significant risks, uncertainties and other factors, including assumptions and projections, for all forward periods. Our actual results may differ materially from any future results expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:
•our substantial amount of indebtedness and its impact on our liquidity, credit ratings and ability to return capital to its shareholders;
•our ability to successfully execute the next phase of our strategic transformation;
•our ability to declare and pay dividends which is subject to certain considerations;
•the impact of the outcomes of legal claims, disputes, regulatory investigations and litigation;
•inflationary trends, including in the price of our input costs, such as raw materials, transportation and energy;
43
Table of Contents
•supply chain disruptions, geopolitical developments, including the Russia-Ukraine war, the Israel-Hamas war and wider Middle East developments (including disruptions to the Red Sea passage) or climate-change related events (including severe weather events in the U.S. and abroad) that may affect our suppliers or procurement of raw materials;
•our ability to attract and retain key employees, and manage turnover of top executives;
•our ability to successfully market to our expanded and diverse customer base;
•our ability to effectively compete in our market and develop and introduce new products that meet customers’ needs;
•changes in demand from large multi-national customers due to increased competition and our ability to maintain “core list” status with customers;
•our ability to successfully develop innovative and cost-effective products that allow customers to achieve their own profitability expectations;
•disruption in the development, manufacture, distribution or sale of our products from international conflicts (such as the Russia-Ukraine war and the Israel-Hamas war), geopolitical events, trade wars, natural disasters, public health crises (such as the COVID-19 pandemic), terrorist acts, labor strikes, political or economic crises (such as the uncertainty related to U.S. government funding negotiations), accidents and similar events;
•the impact of a significant data breach or other disruption in our information technology systems, and our ability to comply with data protection laws in the U.S. and abroad;
•our ability to benefit from our investments and expansion in emerging markets;
•the impact of currency fluctuations or devaluations in the principal foreign markets in which we operate;
•economic, regulatory and political risks associated with our international operations;
•the impact of global economic uncertainty (including increased inflation) on demand for consumer products;
•our ability to integrate the N&B Business and realize anticipated synergies, among other benefits;
•our ability to react in a timely and cost-effective manner to changes in consumer preferences and demands, including increased awareness of health and wellness;
•our ability to meet increasing customer, consumer, shareholder and regulatory focus on sustainability;
•our ability to successfully manage our working capital and inventory balances;
•any impairment on our tangible or intangible long-lived assets;
•our ability to enter into or close strategic transactions or divestments, or successfully establish and manage acquisitions, collaborations, joint ventures or partnerships;
•changes in market conditions or governmental regulations relating to our pension and postretirement obligations;
•the impact of the phase out of the London Interbank Offered Rate (“LIBOR”) on our variable rate interest expense;
•our ability to comply with, and the costs associated with compliance with, regulatory requirements and industry standards, including regarding product safety, quality, efficacy and environment impact;
•defects, quality issues (including product recalls), inadequate disclosure or misuse with respect to the products and capabilities;
•our ability to comply with, and the costs associated with compliance with, U.S. and foreign environmental protection laws;
•the impact of our or our counterparties’ failure to comply with the U.S. Foreign Corrupt Practices Act, similar U.S. or foreign anti-bribery and anti-corruption laws and regulations, applicable sanctions laws and regulations in the jurisdictions in which we operate or ethical business practices and related laws and regulations;
•our ability to protect our intellectual property rights;
•the impact of changes in federal, state, local and international tax legislation or policies and adverse results of tax audits, assessments, or disputes;
•the impact of any tax liability resulting from the N&B Transaction; and
•our ability to comply with data protection laws in the U.S. and abroad.
44
Table of Contents
The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. In addition, you should consult other disclosures made by the Company (such as in our other filings with the SEC or in company press releases) for other factors that may cause actual results to differ materially from those projected by the Company. Please refer to Part I, Item 1A, “Risk Factors,” of the 2023 Form 10-K for additional information regarding factors that could affect our results of operations, financial condition and liquidity.
We intend our forward-looking statements to speak only as of the time of such statements and do not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions or results. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this report or included in our other periodic reports filed with the SEC could materially and adversely impact our operations and our future financial results.
Any public statements or disclosures made by us following this report that modify or impact any of the forward-looking statements contained in or accompanying this report will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this report.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
There are no material changes in market risk from the information provided in our 2023 Form 10-K, except for the cross currency swap agreements.
We use derivative instruments as part of our interest rate risk management strategy. We have entered into certain cross currency swap agreements in order to mitigate a portion of our net European investments from foreign currency risk. As of September 30, 2024, these swaps were in a liability position with an aggregate fair value of $164 million. Based on a hypothetical decrease or increase of 10% in the value of the U.S. dollar against the Euro, the estimated fair value of our cross currency swaps would change by approximately $154 million.

ITEM 4. CONTROLS AND PROCEDURES.
(a) Disclosure Controls and Procedures
The Chief Executive Officer and Chief Financial Officer, with the assistance of other members of our management, have evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of the end of the period covered by this Quarterly Report on Form 10-Q.
We have established controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosure.
(b) Changes in Internal Control over Financial Reporting
The Chief Executive Officer and Chief Financial Officer have also concluded that there have not been any changes in our internal control over financial reporting during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
45
Table of Contents
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
For information that updates the disclosures set forth under Part I, Item 3. “Legal Proceedings” in our 2023 Annual Report on Form 10-K, filed on February 28, 2024 with the SEC (the “2023 Form 10-K”), refer to Note 17 to the “Consolidated Financial Statements” in this Form 10-Q.

ITEM 1A. RISK FACTORS.
Refer to Part I, Item 1A, “Risk Factors,” of our 2023 Form 10-K and the information contained in this Quarterly Report on Form 10-Q and our other reports and registration statements filed with the SEC. There have been no material changes with respect to the risk factors disclosed in our 2023 Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.

ITEM 5. OTHER INFORMATION.
Rule 10b5-1 Trading Plans
During the quarter ended September 30, 2024, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “10b5-1 trading arrangement”) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.

ITEM 6. EXHIBITS.
31.1
31.2
32
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extensions Schema
101.CALXBRL Taxonomy Extension Calculation Linkbase
101.DEFXBRL Taxonomy Extension Definition Linkbase
101.LABXBRL Taxonomy Extension Label Linkbase
101.PREXBRL Taxonomy Extension Presentation Linkbase
104Cover Page Interactive File (formatted as Inline XBRL and contained in Exhibit 101)
46
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Dated:November 5, 2024By:/s/ J. Erik Fyrwald
J. Erik Fyrwald
Chief Executive Officer and Director (Principal Executive Officer)
Dated:November 5, 2024By:/s/ Glenn Richter
Glenn Richter
Executive Vice President, Chief Financial & Business Transformation Officer (Principal Financial Officer)
Dated:November 5, 2024By:/s/ Beril Yildiz
Beril Yildiz
Senior Vice President, Corporate Controller and Chief Accounting Officer (Principal Accounting Officer)
47
Document

Exhibit 31.1
CERTIFICATION
I, J. Erik Fyrwald, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of International Flavors & Fragrances Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 5, 2024
By: /s/ J. Erik Fyrwald
Name: J. Erik Fyrwald
Title:Chief Executive Officer

Document

Exhibit 31.2
CERTIFICATION
I, Glenn Richter, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of International Flavors & Fragrances Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Dated: November 5, 2024
By: /s/ Glenn Richter
Name: Glenn Richter
Title:Executive Vice President, Chief Financial & Business Transformation Officer

Document

Exhibit 32


CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of International Flavors & Fragrances Inc. (the "Company") for the quarterly period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), J. Erik Fyrwald, as Chief Executive Officer, and Glenn Richter, as Chief Financial & Business Transformation Officer, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
By: /s/ J. Erik Fyrwald
Name:
J. Erik Fyrwald
Title:Chief Executive Officer
Dated:November 5, 2024
By: /s/ Glenn Richter
Name: Glenn Richter
Title:Executive Vice President, Chief Financial & Business Transformation Officer
Dated:November 5, 2024